

INFORMAZIONI PERSONALI



Donato Zipeto

Dipartimento di Neuroscienze, Biomedicina e Movimento, Università di Verona
Strada le Grazie 8 - 37134 Verona (Italia)

☎ (+39) 045 8027204 (+39) 366 1000625

✉ donato.zipeto@univr.it

🌐 <http://www.medicina.univr.it/foi/main?ent=persona&id=1428&lang=it>

💬 Zoom PMI: 858 903 4223

Sesso Maschile | Data di nascita 24/01/1966 | Nazionalità Italiana

Esperienza lavorativa

Da Ottobre 2025
dal 2014 al 2025
dal 2002 al 2014

Pannelli ERC 2024: LS6_5 "Biology of pathogens"; LS2_2 "Gene editing"
Professore Ordinario in Biologia Molecolare, Università di Verona, Italia
Professore Associato in Biologia Molecolare, Università di Verona, Italia
Ricercatore in Biologia Molecolare, Università di Verona, Italia

Insegnamenti (SSD BIOS-08/A, già BIO/11):

- Biologia molecolare, Corso di Laurea Magistrale a ciclo unico, Facoltà di Medicina, dal 2010
- Basi di Virologia molecolare e terapia genica, Dipartimento di Biotecnologie, dal 2015
- Farmacogenomica e terapia genica Dipartimento di Biotecnologie, 2011-2014
- Retrovirus umani: HIV e AIDS, Facoltà di Medicina, 2010-2022
- Zoonosi e virus emergenti, Facoltà di Medicina, 2014-2023
- Insegnamenti di Biologia Molecolare (vettori virali e terapia genica) nelle Scuole di specializzazione di area sanitaria: Patologia clinica e biochimica clinica, Malattie infettive e tropicali, Medicina dello sport e dell'esercizio fisico, dal 2010
- Scuola di dottorato in Scienze della vita e della salute, Dottorato in Scienze della vita e della salute applicate (dal 2013), Bioscienze (2007-2012), Genomica applicata alla salute (2003-2006)

Partecipazione alle commissioni istituite per gli esami di profitto dei suddetti insegnamenti dal 2002.

Attività internazionali come valutatore

- 2026: Expert evaluator, Ha DEA/UE, call EU4H-2025-HERA-PJ - REA/UE, MSCA-PF 2026
- 2025: Expert evaluator, HaDEA/UE, call EU4H-2024-PJ-03
- 2025: Expert evaluator, HaDEA/UE, call 2025-HORIZON-HLTH-2025-01-DISEASE-07
- 2024: Expert evaluator, HaDEA/UE, HORIZON- HLTH-2024-DISEASE-03-14-two-stage, Stage 2
- 2024: Expert evaluator, REA/UE, HORIZON-JU-GH-EDCTP3-2024-01-01-two-stage, Stage 1
- 2024: Expert evaluator, HaDEA/UE EU4Health – Jas 3rd Wave 2023
- 2023: Expert evaluator, HaDEA/UE, HORIZON-HLTH-2024-DISEASE-03-14-two-stage, Stage 1
- 2023: Expert evaluator, REA/UE, HORIZON-MSCA-2023-PF-01-01
- 2023: Expert evaluator, HaDEA/UE, HORIZON-HLTH-2023-DISEASE-03-07
- 2021-2022: Expert evaluator, European Commission, REA, Horizon Europe, MSCA-PF-01
- 2015-2020: Expert evaluator, European Commission, REA, H2020-HSCA-IF, LIF Panel
- 2020: Project expert evaluator, Latvian Council of Science
- 2016-2017: post-project evaluator, Baltinfect Project, Riga Stradina University, Riga (LV)
- 2014-2021: GHIT Fund Reviewer and evaluator, Japanese R&D for Global Health
- 2014: Expert evaluator, European Commission, H2020-PCH-2014-two-stage (01, 03, 17, 18, 22)
- 2010-2014: Expert evaluator, European Commission, REA, FP7-PEOPLE, Life Panel
- 2009: Evaluator NHLS Research Trust Grant
- 2002-2003: Assistant/Coordinator, European and Developing Countries Clinical Trials Partnership (EDCTP), Milestone 4

Compiti istituzionali accademici

- 2025-2027: Delegato della Rettrice per la Comunità Studentesca e Campus Life
- 2018-2021 e 2021-2024: Rappresentante dei professori associati della macroarea "Scienze della vita e della salute", Senato Accademico dell'Università di Verona; membro della Commissione Edilizia e Spazi
- 2015-2018: Rappresentante dei professori associati nel Consiglio di Dipartimento, Dipartimento di Neuroscienze, Biomedicina e Movimento, Università di Verona; membro Commissione FUR
- 2010-2014: Rappresentate dei Ricercatori, Facoltà di Medicina e Chirurgia, Senato Accademico; Membro della Commissione Ricerca; Membro della Commissione Risorse Economiche e

Strutturali, Facoltà di Medicina e Chirurgia, Università di Verona.

- | | |
|------------------|--|
| Dal 1999 to 2001 | Ricercatore associato, "Poste Rouge" CNRS
ANRS Research Fellow - IPBS-CNRS, Tolosa, Francia
Partecipazione alla start-up biotecnologica "GeneINTEL", Francia |
| dal 1997 al 1998 | Research Fellow - Unité D'Immunologie Virale, Department des Retrovirus et du SIDA, Institut Pasteur, Paris, France - Marie Curie" Research Training Grant, European Commission |
| dal 1993 al 1996 | Research Fellow - Center for AIDS Research (CFAR), Stanford University California, USA: Italian Ministry of Health, AIDS Fellowship (1993-1994) and Stanford University Medical Center (1995-1996) |
| dal 1989 al 1993 | Borsista di ricerca - IRCCS Policlinico S. Matteo, Pavia, Italia e IGBE-CNR, Pavia, Italia
Borsista di ricerca - Ministero della Sanità italiano, borsa di studio sull'AIDS (1992-1993) |

ABILITAZIONI, ISTRUZIONE E FORMAZIONE

- | | |
|----------------|---|
| Luglio 2024 | Abilitazione scientifica nazionale (ASN) a Professore Ordinario, settore Microbiologia e Microbiologia Clinica - GSD 06/MEDS-03, SSD MEDS-03/A (precedente SC 06/A3 e SSD MED/07) |
| Dicembre 2023 | Abilitazione scientifica nazionale (ASN) a Professore Ordinario, settore Biologia Molecolare - GSD 05/BIOS-08, SSD BIOS-08/A (precedente SC E5/02 e SSD BIO/11) |
| Novembre 1996 | PhD Fellow in Infectious Diseases, Stanford University, California, USA |
| Dicembre 1990 | Esame di Stato per l'abilitazione alla professione di Biologo, Università di Pavia, Italia |
| Settembre 1989 | Laurea in Scienze Biologiche (110 e lode), Università di Pavia, Italia |

COMPETENZE PERSONALI

- | | |
|--------------|-------------------------|
| Lingua madre | Italiano |
| Inglese | Letto, scritto, parlato |
| Francese | Letto, parlato |

- | | |
|--------------------------------|--|
| Competenze tecniche e digitali | <ul style="list-style-type: none"> • Biologia Molecolare, Virologia Molecolare, Biologia Cellulare, Immunologia • Computer: linguaggi di programmazione C; Sistemi operativi Unix, Linux, Mac OSX, Windows, Bioinformatica, Elaborazione testi, Analisi di database, Analisi statistica • 1991 Sviluppo di un programma informatico per il calcolo dei parametri della PCR, distribuito da M-Medical Genenco, Firenze, Italia |
|--------------------------------|--|

Finanziamenti per la ricerca

Sperimentatore principale, leader di gruppo di ricerca dal 2003

Finanziamenti:

- 2023-2025: Bando PRIN 2022, Coordinatore dell'Unità di Ricerca, Progetto: "Definizione fine della risposta sistemica e mucosale in soggetti vaccinati contro la SARS-CoV-2", Ministero dell'Università e della Ricerca (Ministero Italiano dell'Università e della Ricerca)
- 2020: Fondazione Brain Research Verona, progetto "Neurotropismo della SARS-CoV-2: aspetti virologici, cellulari, molecolari e patogenetici".
- 2019: Gilead Fellowship Program Grant, progetto "Disordini neurocognitivi associati all'HIV: un approccio clinico, virologico e immunologico per la definizione precoce di biomarcatori".
- 2011: 6th FP, "Analisi dell'interazione tra HLA-C e HIV-1 Env". Premio per l'innovazione della Commissione europea EUROPRIZE
- 2007-2011: 6th PQ, "Impresa europea di vaccini e microbicidi". Progetto EUROPRIZE della Commissione europea
- 2007: "Azione Concertata per lo sviluppo di un vaccino contro l'HIV/AIDS". Programma Nazionale di Ricerca sull'AIDS ISS (ICAV), Ministero della Salute, Italia. 45G.41
- 2005: "Induzione di anticorpi neutralizzanti ad ampio spettro contro il virus dell'immunodeficienza umana (HIV) verso un vaccino contro l'AIDS". Programma di Ricerca Scientifica 2005, Fondazione Cariverona
- 2004: "Sviluppo e selezione del vaccino". Programma Nazionale di Ricerca sull'AIDS ISS, Ministero della Salute, Italia. 45F.45

Finanziamenti come componente di gruppo di ricerca:

- 2023: Borsa di studio Fondazione Cariverona "Bando Ricerca e Sviluppo 2023" - Titolo del progetto: "Formulazione di un detergente nanofluido ecologico e implementazione di analisi microbiologiche per abbattere l'impatto ambientale di termodisinfettori per dispositivi biomedicali"

- 2022-2025: Hub-Spoke PNRR MNESYS (Un approccio integrato su più scale per lo studio del sistema nervoso in salute e malattia)
- 2018: Rete proteica del compartimento sinaptico in un modello in vitro di Neuronal Ceroid Lipofuscinosis infantile. Progetto congiunto, Università di Verona/IRCCS Fondazione Stella Maris.
- 2017: Produzione di linee linfocitarie ingegnerizzate con il sistema CRISPR per lo studio delle malattie linfoproliferative (LymphoCRISPR), Progetto congiunto, Università di Verona/Istituto Oncologico Veneto.
- 2010: Progetto RSF 300/09, "Nuovi approcci per il trattamento della fibrosi cistica mediante terapia genica e cellulare", Regione Veneto, 2010.
- 2010: Ministero della Salute, Programma di Ricerca sull'AIDS: "HLA-C e HIV-1: dalla biologia strutturale dell'interazione tra HLA-C e gp120 allo sviluppo di un nuovo vaccino bimodale che induce anticorpi che impediscono l'ingresso virale e innescano l'attività antivirale delle cellule NK". ISS40H92.
- 2005: Ministero della Salute italiano, Programma di Ricerca sull'AIDS: "l'influenza della coinfezione con HTLV-II sulla progressione della malattia da HIV-1".
- 2005: Fondazione Cariverona: "Studio dell'influenza dei retrovirus oncogeni umani "Human T-cell Leukemia Virus" (HTLV) sui processi patogenetici indotti nelle cellule ematopoietiche e del ruolo del citomegalovirus umano sull'insorgenza dell'adenocarcinoma nell'uomo"
- 2002: Ministero della Salute, Programma di Ricerca sull'AIDS "Epitopi critici e conformazionali di gp120: utilizzo di complessi molecolari tra gp120 e proteine cellulari per indurre anticorpi cross-neutralizzanti".

Supervisore e relatore di Tesi

Relatore, co-tutor e tutor per tesi di laurea e di dottorato (10 dottorati di ricerca, 134 tesi Corso magistrale, 1 tesi corso specializzazione medica post-laurea, 12 tesi Corso di studi triennale)

- Dottorato di ricerca in Scienze Applicate alla Vita e alla Salute, Università di Verona
- Dottorato di ricerca in Bioscienze, Università di Verona
- Dottorato di ricerca in Bioscienze, Università di Verona, co-tutorato con l'Università di La Laguna, Tenerife, Spagna.
- Dottorato di ricerca in Genomica applicata alla salute, Università di Verona
- Dottorato di ricerca in Scienze Biomolecolari, Università di Trento
- Dottorato di ricerca in Medicina Molecolare, Università "Vita-Salute San Raffaele, Milano
- Dottorato di ricerca in Scienze Biomediche Cliniche e Sperimentali, Università degli Studi di Milano
- Laurea magistrale in Bioinformatica e Biotecnologie Mediche, Università di Verona
- Laurea magistrale in Biologia della Salute, Facoltà di Scienze, Università di Padova
- Laurea in Biotecnologie, Dipartimento di Biotecnologie, Università di Verona
- Laurea in Biotecnologie Agroindustriali, Università di Verona
- Laurea in Scienze Biologiche, Università degli Studi di Roma "La Sapienza".
- Métrise Biochimie, Orientation Technologies Biologiques, Université Paul Sabatier Toulouse, Francia/Freien Universität Berlin, Germania

Partecipazione a commissioni di dottorato

Componente di commissioni per l'esame finale della Scuola di dottorato:

- "Genetica, Biologia Molecolare e Cellulare", Università di Pavia, 9.1.2020
- "Biotecnologie applicate alle scienze mediche", Università "Vita-Salute San Raffaele, Milano, 20.12.2020
- "Genetica, Biologia Molecolare e Cellulare", Università di Pavia, 27.3.2020

RELATORE A CONFERENZE SU INVITO

- "Development of SARS-CoV-2 IgM after vaccination predicts longer immunity and lower frequency of infection". International Pathology Conference, "Victor Babes" Institute, Bucharest, Romania, November 18, 2022.
- "Response to vaccination in naïve versus previously SARS-CoV-2 infected subjects". PDI 2021, Iasi, Romania, July 24, 2021.
- "Response to vaccination in naïve versus previously SARS-CoV-2 infected subjects". Commissariat à l'énergie atomique et aux énergies alternatives (CEA) Fontenay-aux-Roses, France, 18 June 2021.
- "Vaccine research and testing, up to the Sars-Cov-2 vaccine", Segretariato Italiano Studenti in Medicina (SISM), 21 April 2021.
- "Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?" 49th Conference of the Immunology Society, 3 October 2020, Bucharest, Romania.
- "CRISPR/Cas9: potential, issues and prospects". Department of Biological Sciences, Cyprus University, February 19, 2020; Nicosia, Cyprus.
- "HLA-C stability and HIV-1 associated neurocognitive disorders: a missing piece of the pathogenetic puzzle?". 3rd International Congress Pharmacogenomics and Personalized Diagnosis and Therapy, January 11, 2020, Athens, Greece.
- "HIV-1 and HLA-C: a matter of stability (HIV-1 și HLA-C: o chestiune de stabilitate)". The 48th Conference of the Romanian Society of Immunology, September 19, 2019, Bucharest (Romania)
- "HIV-1 and HLA-C relationship: a matter of Stability". 3rd National Congress of the Italian Society of Virology, Padua (Italy), September 12, 2019.
- "HLA-C and HIV-1: a Matter of Stability". International Conference on Immunity and Immunochemistry iChem-2019, San Francisco (USA), July 2, 2019.
- "New applications of the genome editing techniques to discover bone pathways". Summer School "The basic of bone in health and disease" 2nd edition, University of Verona, 17-21 September 2018.

- "New applications of the genome editing techniques to discover bone pathways". Summer School "Bone across the life span: function, dysfunction and therapy". University of Verona, 2-6.10.2017.
- "CRISPR/Cas9 as a tool for the study of the interactions between viruses and host". The Present and future of genome editing. 9 June 2017, UMG Campus, Catanzaro, Italy.
- "CRISPR/Cas9 as a tool for the study of the interactions between viruses and host". Dermatologic Spring In Iasi – HPV Symposium, 30.3.2017-1.4.2017, Iasi, Romania.
- "HLA-C and HIV-1: friends or foes?" CIBIO-University of Trento (Italy), 12 April 2013.
- "HIV-1 Env and HLA-C association is selective for heavy chains open conformers and excludes $\beta 2m$ ". 4C Meeting, St. George's Hospital, London (UK), 8 April 2013.
- "HIV-1 Env associates with HLA-C open conformers and transports HLA-C on the cell membrane". Workshop on HLA-C and HIV – Villa La Collina, Cadenabbia (Como), 9-11 July 2012.
- "HIV-1 Env glycoprotein and HLA-C associate and increase HIV-1 infectivity" Rational Design of HIV Vaccines and Microbicides – Europrise Network Annual Conference, Prague (Czech Republic), 17 November 2011.
- "HLA-C increases HIV-1 infectivity: a potential target for therapeutic intervention?". Istituto di Genetica Molecolare del CNR, Pavia, 18 January 2011.
- "HLA-C increases HIV-1 infectivity by interacting with the envelope glycoprotein gp120" Rational Design of HIV Vaccines and Microbicides – Europrise Network Annual Conference, Lisbon (Portugal), 18 November 2010.
- "Fusion complexes and CD4-independent Env for the induction of broad spectrum neutralizing antibodies against HIV-1". 12th Annual International Meeting of the Institute of Human Virology, Tropea (Italy), 6 October 2010.
- "HLA-C increases HIV-1 infectivity: a potential target for therapeutic intervention?". Facultad de Medicina, Universidad de La Laguna, Tenerife, Spain, 28 May 2010.
- "Broad spectrum neutralizing antibodies against HIV-1 elicited by immunizing with fusion complexes and CD4-independent gp120/41s". Rational Design of HIV Vaccines and Microbicides – Europrise Network Annual Conference, Budapest (HU), 16 November 2009.
- "Broad spectrum neutralizing antibodies against HIV-1 elicited by immunizing with fusion complexes". 11th Annual International Meeting of the Institute of Human Virology, Baltimore (USA), September 11, 2008.
- "Fusion complexes as immunogens for the induction of broad spectrum neutralizing antibodies against HIV-1". Rational Design of HIV Vaccines and Microbicides, Europrise, Novartis Siena (Italy), 22 November 2007.
- "New immunogens to elicit broad spectrum neutralizing antibodies against HIV-1". Département de Virologie, Institut Pasteur, Paris (France) 2 October 2007.
- "HLA class I increases the efficiency of fusion between the HIV-1 envelope and the target cell membrane and is part of the fusion complex between the gp120/gp41 and the cellular receptors". 8th ECEAR 2006 Conference, Naples (Italy), 27 May 2006.
- "Fusion complexes and CD4-independent gp120s for the induction of HIV-1 neutralizing antibodies". 2005 International Meeting of the Institute of Human Virology, Baltimore (USA) 1 September 2005.
- "Induction of HIV neutralizing antibodies using fusion complexes". Institut Pasteur, Paris (France) 14 June 2005.
- "Induction of HIV neutralizing antibodies using fusion complexes". Scientific Workshop "HIV and vaccines: from basic science to human clinical trials". Research & Progress Foundation, Catania, 7-8 May 2005.
- "Induction of HIV-1 neutralizing antibodies by fusion complexes." 2004 International Meeting of the Institute of Human virology, Baltimore (USA) 3 November 2004.
- "Induction of human immunodeficiency virus (HIV) broad spectrum neutralizing antibodies with fusion complexes." 4th National Congress of The Italian Society of Virology, Orvieto (Italy) September 22, 2004.
- "Fusion complexes as broad spectrum anti-HIV vaccine" – 2003 International Meeting of the Institute of Human Virology, Baltimore, USA, 3 October 2003.
- "Analisi dei cambiamenti conformazionali nella gp120/gp41 del virus HIV nel corso della fusione membranaria per lo sviluppo di un vaccino a largo spettro contro HIV" – Università di Verona, Italy, 20 September 2001.
- "HIV entry: a possible target for a vaccine?" – IRBM (Merck), Pomezia (Rome), Italy, 16 May 2001.
- "HIV entry: a possible target for a vaccine?" – DIBIT S. Raffaele, Milan, Italy, 22 May 2001.
- "Development of an anti-HIV vaccine" – IPBS-CNRS, Toulouse, 30 November 30 2000.
- "Interactions between human cytomegalovirus and chemokines" – ROCHE, Basel (Switzerland), 14 November 1997.
- "Interactions between human cytomegalovirus and chemokines" – TRANSGENE, Strasbourg (France), 29 September 1997.
- "Human cytomegalovirus infection induces chemokines and chemokines receptors" - I.G.B.E.-C.N.R. - D.G.M., Pavia (Italy), 17 July 1997.
- "Human Cytomegalovirus (CMV) DNA in plasma reflects the quantity of CMV DNA present at cellular sites but not symptomatic disease" - Department du SIDA et des Retrovirus, Pasteur Institut, Paris (France), 2 December 1994.
- "HCMV presence in plasma correlates with presence of virus in leukocytes but not with clinical symptoms" - I.G.B.E.-C.N.R., Pavia (Italy), 23 November 1994.
- "Quantification of HCMV DNA in leukocyte cells from immunocompromised patients by mean of Polymerase chain reaction" - Interdepartmental Center for Biotechnologies, University of Ferrara (Italy), 7 October 1992.
- "Use of PCR for Virological diagnosis" - Course "New Laboratory Technologies, 1991" - Modena (Italy), 20 March 1991.
- "Synthetic Oligonucleotides for Virological diagnosis" - Biological Chemistry Institute, Ferrara (Italy), 12 December 1990.
- "Use of PCR for the diagnosis of human Cytomegalovirus" - Istituto Zooprofilattico della Lombardia e dell'Emilia, Brescia (Italy), 19 April 1990.

PREMI

- 2020: Premio "Docente dell'anno", Corso di Laurea Magistrale a Ciclo unico in Medicina e Chirurgia, Università di Verona
- 2019: Gilead Fellowship Program, premio per il progetto "HIV-associated neurocognitive disorders: a clinical, virological and immunological approach to early definition of biomarkers". Milan, 15 October 2019 – Fondazione Catella
- 2011: 6th FP, Innovation Award per il progetto "Analysis of the interaction between HLA-C and HIV-1 Env". European Commission EUROPRISE

AFFILIAZIONI

- Società Italiana di Biofisica e Biologia Molecolare (SIBBM)
- Società Italiana di Virologia (SIV-ISV)
- Marie Curie Fellowship Association (MCFA)
- Trialect (tirocini e corsi di formazione internazionali: CRISPR/Cas9 e Vettori virali)
- "Patto trasversale per la Scienza" (PTS) - www.pattoperlascienza.it

ATTIVITÀ DI
PUBLIC ENGAGEMENT

- Articolo "Il contagio nel mondo" - Primo Informare - Scienze e Tecnologie, Il Mondo, 20.12.97, pag. 96.
- Zipeto D.: "Un vaccino per HIV" - Bioagency 19 Gennaio 2004
- "Speranza contro le malattie del sistema nervoso" - L'Arena, 8 ottobre 2013, pag. 48.
- Virus ed evoluzione ed evoluzione dei virus - UAAR/Città di Verona, 19 febbraio 2016.
- Vaccini: sì o no? Chi ha paura dei vaccini? - Università di Verona, 30 maggio 2017
- "Sei a casa" - TeleArena (trasmissione televisiva), 25 settembre 2018.
- "Università: battaglia alle fake news. Vaccini, il web finisce sotto accusa" - Corriere di Verona/Corriere della Sera (intervista al quotidiano), 26 settembre 2018
- "Chi ha paura dei vaccini?". - VenetoNight/Notte della ricerca (intervento pubblico), 28 settembre 2018.
- "Vaccini e fake news" - Università della Formazione Permanente, Area Cultura e Turismo Comune di Verona, Chiostro di Sant'Eufemia, Verona, 22 ottobre 2018
- "Dalla SARS al Covid-19, cosa insegnano le epidemie del recente passato" - UNIVRMagazine, 30 marzo 2020 (<http://www.univrmagazine.it/2020/03/30/dalla-sars-al-covid-19-cosa-insegnano-le-epidemie-del-recente-passato/>)
- "COVID-19: tutti ignorati" - L'Arena, 11 aprile 2020, pag. 48.
- Tamburin S., Mantovani E., Gruppo InterSERT di Collaborazione Scientifica (GICS), De Bernardis E., **ZIPETO D.**, Lugoboni F.: "Disegno e razionale di uno studio multicentrico osservazionale retrospettivo sul COVID-19 in soggetti in trattamento con disulfiram". Giornale Italiano delle Dipendenze/Medicina delle Dipendenze 40: 26-29 (2020).
- "Vaccini. Ricerca e sperimentazione fino al vaccino contro il Sars-CoV-2". Segretariato Italiano Studenti Medicina (SISM), 21 aprile 2021 (<https://www.youtube.com/watch?v=AFWqN6GUEuM>)
- "Covid-19: nuove osservazioni nella risposta al vaccino contro Sars-CoV-2" - UNIVRMagazine, 3 novembre 2021 (<https://www.univrmagazine.it/2021/11/03/covid-19-nuove-osservazioni-nella-risposta-al-vaccino-contro-sars-cov2/>)
- "CoViD-19: osservazioni nella risposta al vaccino". Focus, 8 novembre 2021 (<https://www.focus.it/scienza/scienze/covid-19-osservazioni-nella-risposta-al-vaccino>)
- "Covid: varianti e vaccini". Corso di formazione e aggiornamento per Docenti - 17-18 gennaio 2022, Museo delle Scienze (MUSE), Trento, Italia. https://www.muse.it/it/news/Archivio/Pagine/NEWS_IMPARA/Covid-varianti-e-vaccini-.aspx
- "Il Covid è davvero finito?". - Università degli Studi, Area Cultura e Turismo Comune di Verona, Chiostro di Sant'Eufemia, Verona, 13 febbraio 2023.
- Radio 24, rubrica "Obiettivo salute - weekend", intervista "Virus: sono buoni o cattivi?". - 13 gennaio 2024. <https://www.radio24.ilsole24ore.com/programmi/obiettivo-salute-weekend/puntata/trasmissione-13-gennaio-2024-120700-2397647803913614>

ATTIVITÀ EDITORIALI

- 2023-2025: Guest Editor per Frontiers in Cellular Neurosciences, argomento "Unravelling the long term effects of COVID-19". (<https://www.frontiersin.org/research-topics/62706/unraveling-the-long-term-effects-of-covid-19>)
- 2023: Redattore associato per Frontiers in Immunology
- 2022: Editor per Frontiers in Bioengineering and Biotechnology, argomento "Nanomateriali per la diagnosi e la terapia delle infezioni virali" (<https://www.frontiersin.org/research-topics/33755/nanomaterials-for-the-diagnosis-and-therapy-of-viral-infections>)
- 2022: Review Editor per Fundamental Virology - Frontiers in Virology

- 2020: Guest Editor per il Journal of Immunology Research, numero speciale su "Inflammation in Cancer: part of the problem or part of the solution?". (<https://new.hindawi.com/journals/jir/si/916706/>)
- 2018: Guest Editor per il Journal of Immunology Research, numero speciale su "Inflammation in Cancer: part of the problem or part of the solution?". (<https://www.hindawi.com/journals/jir/si/567915/>)
- 2003: Relazioni sulle sperimentazioni cliniche in corso per farmaci e vaccini contro l'HIV/ADS, la tubercolosi e la malaria, per la European and Developing Countries Clinical Trial Partnership (EDCTP), Commissione Europea
- Revisore scientifico per riviste specializzate: PNAS, Retrovirology, Vaccine, The Open Autoimmunity Journal, Intervirology, Reviews in Medical Virology., Journal of Virology, Frontiers in Immunology, Frontiers in Neurology, Frontiers in Cellular Neuroscience, Journal of Cellular and Molecular Medicine, Journal of Translational Medicine, Infectious Agents and Cancer, etc.
- Traduttore e correttore scientifico per le società "Biomedical Translations", Palo Alto/Modesto, California, USA (1993-2012) e "Tembua Inc." (2012-2019).
- Consulente (HIV-AIDS) sito "Salute 2000" (<http://www.health2000.net/>).
- Autore per Thomson Reuters, serie "Integrity Disease Briefings":
 - "Influenza" - D. Zipeto, T. Stegmann (2001).
 - "Human Cytomegalovirus" - D. Zipeto, L. Rasmussen (2001).
 - "HIV and AIDS" - D. Zipeto, T. Stegmann (2001).
 - "Herpes Simplex Virus" - D. Zipeto, L. Rasmussen (2002).
 - "Respiratory Syncytial Virus" - D. Zipeto, L. Rasmussen (2002).
 - "Rhinoviruses" - D. Zipeto, L. Rasmussen (2002).
 - "Poxvirus" - D. Zipeto, L. Rasmussen (2003).
 - "SARS" - D. Zipeto, L. Rasmussen (2004).
 - "Rotaviruses" - D. Zipeto, L. Rasmussen (2005).
 - "Epstein-Barr Virus" - D. Zipeto, L. Rasmussen (2006).
 - "Human T-cell Leukemia Viruses" - D. Zipeto, M. Turci (2007)
 - "Influenza" - D. Zipeto (2010)

BREVETTI

- 1998: "Vecteurs dérivés d'anticorps pour le transfert de substances dans les cellules". Avrameas A., Avrameas S., Biondel B., Buttin G., Couderc T., Michelson S., Saron M.F., Ternynck T., **ZIPETO D.** EP1001815B1, WO/1999/007414 (peptide to be used as antiviral agent)
<http://www.sumobrain.com/patents/wipo/Vectors-derived-from-antibodies-transferring/WO1999007414.html>
<http://www.google.com/patents/EP1001815A1?cl=fr>
- 2003: "Single-chain antibody fragments for transferring substances into cells". Avrameas A., Avrameas S., Biondel B., Buttin G., Couderc T., Michelson S., Saron M.F., Ternynck T., **ZIPETO D.** Application 09/497,997, US Patent N. 6,635,248 (B1), Issued October 21, 2003. International A61K35/12; A61K38/00; A61K39/395; A61K45/00; A61K47/48; A61P31/12; A61P31/18; A61P31/22; C07K16/00; C07K16/18; C07K16/28; C07K19/00; C12N1/15; C12N1/19; C12N15/09; C12N5/10; C12N5/20; C12P21/08. European: A61K47/48R; A61K47/48T4K; C07K16/18; C07K16/28.
- 2009: "Vector derived from antibodies for transferring substances into cells". Ternynck T., Avrameas A., Buttin G., Avrameas S., Saron M.F., Biondel B., Couderc T., Michelson S., **ZIPETO D.** Application 10/460,471. US Patent N. 7,628,987 (B2), Issued December 8, 2009. International A61K39/00; A61K39/12. European: C07K16/10K1F; C07K16/44.
<http://www.patentgenius.com/inventedby/ZipetoDonatoParisFR.html> <http://www.patentbuddy.com/Inventor/Zipeto-Donato/12091298> - http://www.directoryinventor.com/inventor/Zipeto_Donato_1.html

NOME	N.	IF (JCR 2025)	QUARTILE (SJR 2025)
AIDS	1	2.9	Q1
AIDS Research and Human Retroviruses	2	1.0	Q3
Antimicrobial Agents and Chemotherapy	1	4.2	Q1
APMIS	1	2.2	Q2
Biomedicines	1	4.5	Q1
Cells	4	6.0	Q1
Cell Communication and Signaling	1	11.6	Q1
Communications Medicine	1	7.4	Q1
Drugs of the Future	1	0.2	Q4
eBioMedicine	2	11.2	Q1
Frontiers in Bioengineering and Biotechnology	1	5.8	Q1
Frontiers in Immunology	4	7.0	Q1
Frontiers in Microbiology	2	5.8	Q1
Frontiers in Neurology	1	3.3	Q2
Frontiers in Oncology	1	3.4	Q2
Genes	1	3.1	Q2
Heliyon	1	3.6	Q1
HIV Medicine	1	3.2	Q1
HLA	1	5.0	Q4
Infectious Agents and Cancer	1	3.2	Q2
Int. Journal of Biochemistry & Cell Biology	1	3.5	Q2
Int. Journal of Molecular Sciences	4	5.6	Q1
Internal and Emergency Medicine	1	4.1	Q1
Investigative Ophthalmology and Visual Science	1	5.5	Q1
Journal of Acquired Immune Deficiency Syndromes	9	2.3	Q1
Journal of Cellular and Molecular Medicine	1	4.7	Q2
Journal of Clinical Microbiology	3	5.9	Q1
Journal of Experimental Medicine	1	3.8	Q1
Journal of General Virology	3	4.3	Q1
Journal of Immunology	1	4.0	Q1
Journal of Immunology Research	1	3.2	Q1
Journal of Infectious Diseases	5	4.1	Q1
Journal of Translational Medicine	1	9.7	Q1
Journal of Virological Methods	1	1.7	Q3
Journal of Visualized Experiments (JOVE)	1	1.2	Q2
Journal of Virology	2	4.1	Q1
Microbes and Infection	1	2.9	Q2
Microbiologica	1	0.43	Q3
Microorganisms	1	4.7	Q1
Molecular and Cellular Probes	1	3.2	Q3
Non-coding RNA	1	4.2	Q2
Pathogens	2	4.1	Q1
Retrovirology	5	3.9	Q1
Science	2	47.3	Q1
Scientific Reports	4	4.9	Q1
Vaccines	1	3.5	Q1
World Journal of Stem Cells	1	4.9	Q2

	ISI Web of Science	Scopus	Google Scholar	Research Gate
N. di pubblicazioni	89	79	225	107
N. di citazioni	2897	3020	4257	3566
H-Index	28	28	32	32

IF totale (JCR 2025): 480,13 IF medio: 5.488 IF* mediano: 4.1		Autore Primo/ultimo/corresponding: 37/85 (43.5%)		ORCID: 0000-0002-2168-4144 Scopus: 55393878400 WoS: P-3041-2019	
Soglie ASN 2021-2026				% Quartili: Q1: 77.6% Q2: 14.1% Q3: 5.9% Q4: 2.4%	* IF mediano: Biochem. & Mol. Biol.: 3.5 Microbiology: 3.5 Virology: 2.85
Articoli/10 anni: 42	Biologia Molecolare Microbiologia e Microbiologia Clinica	Ordinario	Commissario		
Citazioni/15 anni: 1087		SI (3/3)	SI (2/3)		
H-index/15 anni: 19		SI (3/3)	SI (2/3)		

Submitted

- Dobre E.G., Voi M., Orlandi E., De Martinis C., Benna C., Mocellin S., **ZIPETO D.**, Valenti M.T., Neagu M.: "RUNX2 as a Context-Dependent Regulator of Tumor Progression and Immune Modulation in Cutaneous Melanoma". (submitted).
- Dalle Carbonare L., Vareschi A., K. Dervishi, Deiana M., Locatelli E., Minoia A., Piritore F.C., Ruggiero A., Czobor Barbu I., **ZIPETO D.**, Piubelli C., Valenti M.T.: "High-Touch, High-Risk: a microbiome analysis of hospital wheelchairs". (submitted).

Pubblicazioni peer-reviewed:

Impact Factor (IF) e Quartile (Q) dell'anno di pubblicazione o *il più prossimo disponibile

- Vuono R., Allinson K.S.J., **ZIPETO D.**, Temperton N.: "Editorial: Unravelling the Long Term Effects of COVID-19". *Frontiers in Cellular Neuroscience* 20:1926660 (2026) DOI: 10.3389/fncel.2026.1926660 [IF 4.4 – Q2]
- Dalle Carbonare L., Vareschi A., K. Dervishi, Deiana M., Locatelli E., Minoia A., Piritore F.C., Ruggiero A., Czobor Barbu I., **ZIPETO D.**, Piubelli C., Valenti M.T.: "High-Touch, High-Risk: a microbiome analysis of hospital wheelchairs". *Pathogens* 15: 693 (2026) DOI: 10.3390/pathogens15070693 [IF 3.8 – Q1].
- Signoretto C., Caiazza L., De Grandi G., **ZIPETO D.**, Gaibani P.: "Epidemiology and molecular characterization of Mycoplasmosis in northeastern part of Italy, 2023". *Pathogens* 15: 304 (2026) DOI: 10.3390/pathogens15030304 [IF 3.8– Q1].
- Ben Khelifa E., Campese A., Corsi A., Bombieri C., Romanelli M.G., Valenti M.T., **ZIPETO D.**, Castelli M., Lievens P.M.J., Ruggiero A.: "Post-translational modifications in respiratory viruses' infection: novel insights into the development of in vitro models". *International Journal of Molecular Sciences* 26:12174 (2025) DOI: 10.3390/ijms262412174 [3 CIT - IF 4.9 – Q1]
- Voi M., Sangalli A., Milano E.G., De Martinis C., Orlandi E., Tamburini S., Mantovani E., Federico A., Lanzafame M., Lattuada E., Arganaraz G.A., Da Silva B.C.M., Da Silva A.J.D., Casseb J., Arganaraz E.R., Malena M., Ruggiero A., Romanelli M.G., Valenti M.T., Grazioso G., **ZIPETO D.**: "Computational characterisation of peptide binding stability to HLA-C allotypes and its association with HIV-1 infection progression and HIV-1 related neurocognitive impairment". *Frontiers in Immunology* 16: 1703026 (2025). DOI: 10.3389/fimmu.2025.1703026 [IF 5.9 – Q1]
- Piubelli C., Valerio M., **ZIPETO D.**, Orlandi E., Calderr S., Rizzolo F., Barbero K., Vezzelli E., Ganesini N., Zamboni S., Tiberti N., Longoni S.S., Verzè M., Nicolis F., Gobbi F., Gori S.: "Balancing neutralization and tolerance: spike-specific antibodies responses to repeated COVID-19 mRNA vaccine booster in solid cancer patients". *Frontiers in Immunology* 16: 1699177 (2025) DOI: 10.3389/fimmu.2025.1699177 [IF 5.9 – Q1]
- Dalle Carbonare L., Minoia A., Zouari S., Braggio M., Cominacini M., Gaglio S.C., Piritore F.C., Lorenzi P., Meneghel M., Dervishi K., Corsi A., Pedrinolla A., Giurato G., Fiore A., Cesia A., Venturelli M., Schena F., Donadelli M., Mottes M., Romanelli M.G., Perduca M., Crisafulli E., **ZIPETO D.**, Barile L., Valenti M.T.: "Extracellular vesicles from long covid patients promote RUNX2-mediated cellular stress via dysregulated miR-204 and p53 pathway activation". *Cell Communication and Signalling* 23: 508 (2025) DOI: 10.1186/s12964-025-02502-7 [5 CIT - IF 8.9 – Q1]
- Vareschi A., Gaglio S.C., Dervishi K., Zanella G., Lucchi L., Serena E., Jimenez-Lopez C., **ZIPETO D.**, Gaboreanu D.M., Barbu I.C., Leardini C., Perduca M., Dalle Carbonare L., Valenti M.T.: "Evaluation of biocontrol measures to reduce bacterial load and healthcare associated infections". *Microorganisms* 13, 1923 (2025). DOI: 10.3390/microorganisms13081923 [4 CIT - IF 4.2 – Q1]
- Corsi A., De Simone T., Valentino A., Orlandi E., Stefani C., Patuzzo C., Fochi S., Bruno M.G., Trabetti E., Rotondo J., Mazziotta C., Valenti M.T., Ruggiero A., **ZIPETO D.**, Bombieri C., Romanelli M.G.: "MALAT1 expression is deregulated in cell lines knocked out for mirt-34a". *Non-coding RNA* 11: 60 (2025). DOI: 10.3390/ncrna11040060 [1 CIT - IF 3.0 – Q2]
- Dalle Carbonare L., Minoia A., Vareschi A., Piritore F.C., Zouari S., Gandini A., Meneghel M., Elia R., Lorenzi P., Antoniazzi F., Pessola J., **ZIPETO D.**, Romanelli M.G., Guardavaccaro D., Valenti M.T.: "Exploring the Interplay of RUNX2 and CXCR4 in Melanoma Progression". *Cells* 13(5), 408 (2024) DOI: 10.3390/cells13050408 [6 CIT – IF 5.2 – Q1]
- Bombieri C., Corsi A., Trabetti E., Ruggiero A., Marchetto G., Vattemi G., Valenti M.T., **ZIPETO D.**, Romanelli M.G.: "Advanced cellular models for rare diseases study: exploring neural, muscle and skeletal organoids". *International Journal of Molecular Sciences* 25, 1014 (2024) DOI: 10.3390/ijms25021014 [201CIT - IF 4.9 – Q1]
- Fantoni T., Bissoli M., Stefani C., Voi M., Dabija A., Casula R., Minafra D.L., Fonseca Palmeira J., Arganaraz E.R., Mayora-Neto M., Temperton N.J., **ZIPETO D.**, Ruggiero A.: "Pseudotyped viruses as a molecular tool to monitor humoral immune response against SARS-CoV-2 via neutralization assay." *Jove-Journal of Visualized Experiments* 201, e65658 (2023) DOI: 10.3791/65658 [IF 1.2 – Q3]
- Gaglio S.C., Perduca M., **ZIPETO D.**, Bardi G.: of "Efficiency of chitosan nanocarriers in vaccinology for mucosal immunization". *Vaccines* 11:1333 (2023) DOI: 10.3390/vaccines11081333 [32 CIT – IF 7.8– Q1]
- Dalle Carbonare L., Gomez-Lira M., Minoia A., Bertacco J., Orsi S., Gandini A., Antoniazzi F., **ZIPETO D.**, Mottes M., Bhandary L., Guardavaccaro D., Valenti M.T.: "Expression of FBXW11 in normal and disease-associated osteogenic cells". *Journal of Cellular and Molecular Medicine*, Article ID JCM-17767 (2023) DOI 10.1111/jcmm.17767 [6 CIT – IF 5.3 – Q2]
- Bardi G., **ZIPETO D.**, Neagu M., Nikitovic D.: "Editorial: Nanomaterials for the diagnosis and therapy of viral infections". *Frontiers in Bioengineering and Biotechnology* 11: 1192393 (2023) DOI 10.3389/fbioe.2023.1192393[IF 5.7 – Q1/Q2]
- Piubelli C., Ruggiero A., Calciano L., Mazzi C., Castilletti C., Tiberti N., Calderr S., Verzè M., Longoni S.S., Accordini S., Bisoffi Z., **ZIPETO D.**: "Subjects who developed SARS-CoV-2 specific IgM-S after vaccination show a longer humoral immunity and a lower frequency of infection". *eBioMedicine* 89: 104471 (2023) DOI: 10.1016/j.ebiom.2023.104471 [8 CIT – IF 11.1 – Q1]
- Stefani C., Sangalli A., Locatelli E., Federico T., Malerba G., Romanelli M.G., Argañaraz GA, Da Silva BCM, Da Silva AJD, Casseb J., Argañaraz ER, Ruggiero A., **ZIPETO D.**: "Increased prevalence of HLA-C unstable variants in HIV-1 rapid progressor patients". *International Journal of Molecular Sciences* 23, 14852 (2022) DOI: 10.3390/ijms232314852 [3 CIT- IF 6.208 – Q1/Q2]
- Ruggiero A., Stefani C., Sangalli A., Locatelli E., Federico T., Malerba G., Romanelli M.G., Arganaraz G.A., Da Silva Bosco C.M., Duarte Da Silva A.J., Casseb J., Arganaraz E.R., **ZIPETO D.**: "Rapid HIV progression in patients with increased prevalence of unstable HLA-C variants". *HIV Medicine*, 24 (s3), pp.34-35. (2022) WOS:001042880500048 [IF 3.094 – Q2]
- Ruggiero A., Piubelli C., Calciano L., Accordini S., Valenti M.T., Dalle Carbonare L., Siracusano G., Temperton N., Tiberti N., Longoni S.S., Pizzato M., Accordini S., Fantoni T., AMSLV group, Lopalco L., Beretta A., Bisoffi Z., **ZIPETO D.**: "SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals". *eBiomedicine* 77:103888 (2022) DOI: 10.1016/j.ebiom.2022.103888 [53 CIT – IF 11.205 – Q1]
- Siracusano G., Ruggiero A., Bisoffi Z., Piubelli C., Dalle Carbonare L., Valenti M.T., Mayora-Neto M., Temperton N., Lopalco L., **ZIPETO D.**: "Differential

- decay of antibody response and sensitivity to VOCs in BNT162b2 vaccinees after 15 weeks in naïve and previously infected subjects". *Journal of Translational Medicine* 20:22 (2022). DOI: 10.1186/s12967-021-03208-3 [14 CIT – IF 8.448 – Q1]
21. Dalle Carbonare L., Valenti M.T., Bisoffi Z., Piubelli C., Pizzato M., Accordini S., Mariotto S., Ferrari S., Minoia A., Bertacco J., Li Vigni V., Dorelli G., Crisafulli E., Alberti D., Masin L., Tiberti N., Longoni S.S., Lopalco L., Beretta A., **ZIPETO D.**: "Serology study after BNT162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve". *Communications Medicine* 1: 38 (2021). DOI: 10.1038/s43856-021-00039-7 [20 CIT – IF 6.3* – Q1]
 22. Innamorati G., Wilkie T., Malpeli G., Paiella S., Grasso S., Rusev B., Leone B.E., Valenti M.T., Dalle Carbonare L., Cheri S., Giacomazzi A., Zanotto M., Guardini V., Deiana M., **ZIPETO D.**, Serena M., Parenti M., Guzzi F., Lawlor R.T., Malerba G., Mori A., Malleo G., Giacomello L., Salvia R., Bassi C.: "Ga15 in early onset of pancreatic ductal adenocarcinoma". *Scientific Reports* 11: 14922 (2021). DOI: 10.1038/s41598-021-94150-3 [11 CIT – IF 4.380 – Q1]
 23. Valenti M.T., Dalle Carbonare L., **ZIPETO D.**, Mottes M.: "Control of the autophagy pathway in osteoarthritis: key regulators, therapeutic targets, therapeutic strategies". *International Journal of Molecular Sciences*, 22, 2700 (2021) DOI: 10.3390/ijms22052700 [45 CIT – IF 5.924 – Q1/Q2]
 24. Tamburin S., Mantovani E., Gruppo InterSERT di Collaborazione Scientifica (GICS), De Bernardis E., **ZIPETO D.**, Lugoboni F.: "COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder". *Internal and Emergency Medicine*: s11739-021-02633-y (2021). DOI: 10.1007/s11739-021-02633-y [20 CIT – IF 3.397 – Q1]
 25. Beretta A., Cranage M., **ZIPETO D.**: "Is cross-reactive immunity triggering COVID-19 immunopathogenesis?" *Frontiers in Immunology*, 11: 567710 (2020). DOI: 10.3389/fimmu.2020.567710 [47 CIT – IF 5.085 – Q1]
 26. **ZIPETO D.**, da Fonseca Palmeira, J., Arganaraz, A., Arganaraz, E.R.: "ACE2/ADAM17 interplay may be the main risk factor for COVID-19". *Frontiers in Immunology* 11: 576745 (2020). DOI: 10.3389/fimmu.2020.576745 [229 CIT – IF 5.085 – Q1]
 27. Malnati M., Biswas P., Ugolotti E., di Marco E., Sironi F., Parolini F., Garbarino L., Mazzocco M., **ZIPETO D.**, Biassoni R.: "A fast and reliable method for detecting SNP rs67384697 (Hsa-miR 148a binding site) by a single run of allele-specific real-time PCR". *HLA* 2020; 96: 312-322 (2020). DOI:10.1111/tan.13971 [2 CIT – IF 4.513 – Q4]
 28. Fochi S., Lorenzi P., Galasso M., Stefani C., Trabetti E., **ZIPETO D.**, Romanelli M.G.: "The emerging role of RBM20 and PTBP1 ribonucleoproteins in heart development and cardiovascular diseases". *Genes* 11: 402 (2020). DOI:10.3390/genes11040402 [36 CIT – IF 3.759 – Q2]
 29. Deiana M., Dalle Carbonare L., Serena M., Cheri S., Mutascio S., Gandini A., Innamorati G., Lorenzi P., Cumerlato M., Bertacco J., Antoniazzi F., Romanelli M.G., Mottes M., **ZIPETO D.**, Valenti M.T.: "A potential role of RUNX2-RUNT domain in modulating the expression of genes involved in bone metastases: an in vitro study with melanoma cells". *Cells* 9: 751 (2020). DOI: 10.3390/cells9030751 [9 CIT – IF 64.366 – Q1]
 30. Valenti M.T., Pietrobello A., Romanelli M.G., Malerba G., **ZIPETO D.**, Mottes M., Dalle Carbonare L.: "Molecular and lifestyle factors modulating obesity disease". *Biomedicines* 8: 46 (2020). DOI: 10.3390/biomedicines8030046 [6 CIT – IF 4.717 – Q1]
 31. Mantovani E., Lugoboni F., Federico A., **ZIPETO D.**, Tamburin S.: "Benzodiazepine use and HIV-associated neurocognitive impairment: which comes first?". *JAIDS Journal of Acquired Immune Deficiency Syndrome* 83 (4): e26-e27 (2020). DOI: 10.1097/QAI.0000000000002278 [IF 3.475 – Q1].
 32. Fochi S., Ciminale V., Trabetti E., Bertazzoni U., D'Agostino D., **ZIPETO D.**, Romanelli M.G.: "NF-κB and microRNA deregulation mediated by HTLV-1 Tax and HBZ". *Pathogens* 8: 290 (2019). DOI: 10.3390/pathogens8040290 [26 CIT – IF 3.405 – Q1/Q2]
 33. Piccaluga P.P., Visani A., Peron C., Rigotti F., Agostinelli C., Righi S., Diani E., Ligozzi M., Carelli M., Ponti C., Bon I., **ZIPETO D.**, Landolfo S., Gibellini D.: "Interferon Gamma Inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma" *Heliyon* 5: e02643 (2019) doi: 10.1016/j.heliyon.2019.e02643 [6 CIT – IF 3.776* – Q1]
 34. Valenti M.T., Dalle Carbonare L., Serena M., **ZIPETO D.**: "CRISPR/Cas System: an emerging technology in Stem Cells research". *World Journal of Stem Cells* 11: 937-956 (2019) DOI: 10.4252/wjsc.v11.i11.937 [44 CIT – IF 3.534 – Q2]
 35. Deiana M., Malerba G., Dalle Carbonare L., Cheri S., Patuzzo C., Tsenov G., Moron Dalla Tor L., Mori A., Saviola G., **ZIPETO D.**, Schena F., Mottes M., Valenti M.T.: "Physical activity prevents cartilage degradation: a metabolomics study pinpoints the involvement of Vitamin B6". *Cells* 8: 1374 (2019). DOI: 10.3390/cells8111374 [19 CIT – IF 5.656 – Q1]
 36. Fochi S., Bergamo E., Serena M., Mutascio S., C. Journo, R. Mahieu, Ciminale V., Bertazzoni U., **ZIPETO D.**, Romanelli M.G.: "TRAF3 is required for NF-κB pathway activation mediated by HTLV Tax proteins" *Frontiers in Microbiology* 10: 1302 (2019) DOI: 10.3389/fmicb.2019.01302 [20 CIT – 4.259 – Q1]
 37. Cecconi D., Brandi J., Manfredi M., Serena M., Dalle Carbonare L., Deiana M., Cheri S., Parolini F., Gandini A., Marchetto G., Innamorati G., Avanzi F., Antoniazzi F., Marengo E., Tiso N., Mottes M., **ZIPETO D.**, Valenti M.T.: "RUNX2 stimulates angiogenesis through the RUNT domain in melanoma". *Scientific Reports* SREP-19-00805 (2019) DOI: 10.1038/s41598-019-44552-1 [23 CIT – IF 4.011 – Q1]
 38. Neagu M., Constantin C., Popescu I.D., **ZIPETO D.**, Tzanakakis G.N., Nikitovic D., Fenga C., Stratakis C., Spandidos D.A., Tsatsakis A.M.: "Inflammation and metabolism in cancer cell – mitochondria key player." *Frontiers in Oncology* 9: 348 (2019) DOI 10.3389/fonc.2019.00348 [1301 CIT – IF 4.137 – Q1/Q2]
 39. Neagu M., **ZIPETO D.**, Popescu I.D.: "Inflammation in Cancer: Part of the problem or Part of the Solution?". *Journal of Immunology Research* 2019, Article ID 5403910 (2019) DOI: 10.1155/2019/5403910 [6 CIT – IF 3.404 – Q1]
 40. Lorenzi P., Sangalli A., Fochi S., Dal Molin A., Malerba G., **ZIPETO D.**, Romanelli M.G.: "RNA-binding proteins RBM20 and PTBP1 regulate the alternative splicing of FHOD3". *International Journal of Biochemistry & Cell Biology* 106: 74-83 (2019) DOI: 10.1016/j.biocel.2018.11.009 [24 CIT – IF 3.544 – Q2]
 41. Deiana M., Dalle Carbonare L., Serena M., Cheri S., Parolini F., Gandini A., Marchetto G., Innamorati G., Manfredi M., Marengo E., Brandi J., Cecconi D., Mori A., Mina M., Antoniazzi F., Mottes M., Tiso N., Malerba G., **ZIPETO D.**, Valenti M.T.: "New insights into the role of RUNX2 Runt domain in melanoma cells proliferation and migration". *Cells* 7 (11): 220 (2018), doi: 10.3390/cells7110220 [23 CIT – 4.829 – Q1]
 42. **ZIPETO D.**, Serena M., Mutascio S., Parolini F., Diani E., Guizzardi E., Muraro V., Lattuada E., Rizzardo S., Malena M., Lanzafame M., Malerba G., Romanelli M.G., Tamburin S., Gibellini D.: "HIV-1-associated neurocognitive disorders: is HLA-C binding stability to β2-microglobulin a missing piece of the pathogenetic puzzle?" *Frontiers in Neurology* 9: 791 (2018). doi: 10.3389/fneur.2018.00791 [15 CIT – IF 3.508 – Q1/Q2]
 43. Fochi S., Mutascio S., Bertazzoni U., **ZIPETO D.**, Romanelli M.G.: "HTLV deregulation of the NF-κB pathway: an update on Tax and antisense protein role". *Frontiers in Microbiology* 9: 285 (2018) [61 CIT – IF 4.019 – Q1].
 44. Parolini F., Biswas P., Serena M., Sironi F., Muraro V., Guizzardi E., Cazzoletti L., Scupoli M.T., Gibellini D., Ugolotti E., Biassoni R., Beretta A., Malnati M., Romanelli M.G., **ZIPETO D.**: "Stability and expression levels of HLA-C on the cell membrane modulate HIV-1 infectivity". *Journal of Virology* 92: e017111-17 (2018) DOI: 10.1128/JVI.01711-17. [18 CIT – IF 4.368 – Q1]

45. Piccaluga P.P., Agostinelli C., Righi S., Rossi M., Ciccone M., Re M.C., Musumeci G., Diani E., Signoretto C., Bon I., Piccin O., Cuneo A., Tripodo C., Ponti C., **ZIPETO D.**, Landolfo S., Gibellini D.: "IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia". *APMIS*. 125: 511-522 (2017). doi: 10.1111/apm.12692. [9 CIT – IF 1.795 – Q2]
46. Serena M., Parolini F., Biswas P., Sironi F., Blanco-Miranda A., Zoratti E., Scupoli M.T., Ziglio S., Valenzuela-Fernandez A., Gibellini D., Romanelli M.G., Siccardi A., Malnati M., Beretta A., **ZIPETO D.**: "HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity". *Scientific Reports* 7, 40037; (2017) doi:10.1038/srep40037 [18 CIT – IF 2016 4.259 – Q1]
47. Serena M., Giorgietti A., Busato M., Gasparini F., Diani E., Romanelli M. G., **ZIPETO D.**: "Molecular Characterization of HIV-1 Nef and ACOT8: Insights from in silico structural prediction and in vitro functional assays". *Scientific Reports* 6, 22319, doi:10.1038/srep22319 (2016). [9 CIT – IF 5.228 – Q1]
48. Serena M., Gasparini F., Astone D., Calligaris C., Muddei M., Giorgietti A., **ZIPETO D.**: "Human Thioesterase 8 and HIV-1 Nef interactions: insights from in silico predictions and in vitro assays". *Journal of Acquired Immune Deficiency Syndromes* Vol. 67: 90. P-D9. doi: 10.1097/01.qai.0000456198.95066.e2 (2014) ISSN 1525-4135 [IF 4.394 – Q1]
49. Lo Monaco E., Tremante E., Biswas P., Cranage M. P., **ZIPETO D.**, Beretta A., Giacomini P.: "Comment on "Influence of HLA-C expression level on HIV control". *Science* 314: 1175 (2013) [6 CIT – IF 31.027 – Q1]
50. Garcia-Exposito L., Ziglio S., Barroso-Gonzales S., De Armas-Rillo L., Valera M. S., **ZIPETO D.**, Machado J.D., Valenzuela-Fernandez A.: "Gelsolin activity controls efficient early HIV-1 infection". *Retrovirology* 10: 39 (2013). [39 CIT – IF 5.657 – Q1]
51. **ZIPETO D.**, Beretta A.: "HLA-C and HIV-1: friends or foes?". *Retrovirology* 9: 39 (2012). [33 CIT – IF 6.470 – Q1]
52. Ziglio S., Astone D., Danesin G., Racchioli P., Blanco A., **ZIPETO D.**: "Association Analysis Between HIV-1 Env and HLA-C Using Bimolecular Fluorescence Complementation". *Journal of Acquired Immune Deficiency Syndromes* Vol. 59: Supplement 1, #78. doi: 10.1097/01.qai.0000413799.87274.a3 (2012) Online ISSN 1077-9450 [IF 4.425. Q1]
53. **ZIPETO D.**, Beretta A.: "HIV-1 Env and HLA-C: Friends or Foes? " *Journal of Acquired Immune Deficiency Syndromes* 59: Supplement 1, #77. doi: 10.1097/01.qai.0000413798.79651.e7 (2012) Online ISSN 1077-9450 [IF 4.425. Q1]
54. Turci M., Racchioli P., Ziglio S., Astone D., Blanco A., **ZIPETO D.**: "HLA-C associates with Env and Increases HIV-1 infectivity". *Journal of Acquired Immune Deficiency Syndromes* 56 Supplement 2, # 65. doi: 10.1097/01.qai.0000397343.00180.17 (2011). Online ISSN 1077-9450 [IF 4.262 – Q1]
55. Astone D., Rossolillo P., Matucci A., Racchioli P., Cara A., **ZIPETO D.**: "Fusion complexes and CD4-independent Env for the induction of broad spectrum neutralizing antibodies against HIV-1". *Journal of Acquired Immune Deficiency Syndromes* 56 Supplement 2, #65. doi: 10.1097/01.qai.0000397342.18106.3f (2011). Online ISSN 1077-9450 [IF 4.262 – Q1]
56. Baroni, M., Matucci, A., Scarlatti, G., Soprana, E., Rossolillo, P., Lopalco, L., **ZIPETO, D.**, Siccardi, A.G., De Santis, C.: "HLA-C is necessary for optimal HIV-1 infection of human peripheral blood CD4 lymphocytes". *Journal of General Virology* 91 (1): 235-241 (2010). [5 CIT – IF 3.260 – Q1]
57. Bender, C., **ZIPETO, D.**, Bidoia, C., Costantini, S., Zamò, A., Menestrina, F., Bertazzoni, U.: "Analysis of colorectal cancers for human cytomegalovirus presence". *Infectious Agents and Cancer* 4: 6 (2009). [23 CIT – 2.071 – Q2/Q3]
58. Matucci A., Rossolillo P., Turci M., Racchioli P., Siccardi A.G., Beretta A., **ZIPETO D.**: "Presence and role of HLA-C in HIV-1 infection". *Journal of Acquired Immunodeficiency Syndromes* 51: #137 p. 60 (2009). ISSN 1525-4135 [IF 4.570 – Q1]
59. Rossolillo P., Matucci A., Racchioli P., Mainetti L., Dispinseri S., Scarlatti G., **ZIPETO D.**: "Broad Spectrum neutralizing antibodies against HIV-1 elicited by immunizing with fusion complexes". *Journal of Acquired Immunodeficiency Syndromes* 51: 143 (2009). ISSN 1525-4135 [IF 4.570 – Q1]
60. Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giulii Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lefeuvre A, La Placa M, Lewis J, Lillo F, Lisiewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Samgadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tomesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Vamier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, **ZIPETO D.**: "Unsung hero Robert C. Gallo". *Science* 323: 206-207 (2009). [5 CIT- IF 28.103 – Q1]
61. Matucci, A., Rossolillo, P., Baroni, M., Siccardi, A. G., Beretta, A., **ZIPETO, D.**: "HLA-C increases HIV-1 infectivity and is associated with gp120". *Retrovirology*, 5: 68 (2008). [15 CIT – IF 4.040 – Q1]
62. Matucci, A., Rossolillo, P., Sala, S., Lopalco, L., Siccardi, A., Bertazzoni, U., **ZIPETO, D.**: "HLA-C increases fusion efficiency between the HIV-1 envelope and the cell membrane and is part of the fusion complex". *Retrovirology*, 3 (Suppl. I): P70 (2006). ISSN 1742-4960 [IF 4.040* - Q1]
63. **ZIPETO, D.**, Matucci, A., Ripamonti, C., Scarlatti, G., Rossolillo, P., Turci, M., Sartoris, S., Tridente, G., Bertazzoni, U.: "Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes." *Microbes and Infection*, 8 (6): 1424-1433 (2006). [7 CIT – IF 3.154 – Q1]
64. Turci, M., Pilotti, E., Ronzi P., Magnani, G., Boschini, A., Parisi, S.G., **ZIPETO, D.**, Lisa, A., Casoli, C., Bertazzoni, U.: "Coinfection with HIV-1 and HTLV-II in intravenous drug users is associated with delayed progression to AIDS." *Journal of Acquired Immunodeficiency Syndromes*, 41 (1): 100-106 (2006). [49 CIT – IF 3.871 – Q1]
65. **ZIPETO, D.**, Matucci, A., Rossolillo, P., Ripamonti, C., Scarlatti, G., Lopalco, L., Hazan, U., Bertazzoni, U.: "Fusion complexes and CD4-independent gp120s for the induction of HIV-1 neutralizing antibodies". *Retrovirology* 2 (Suppl. I): S121 (2005). ISSN 1742-4960 [IF 4.040* - Q1]
66. Turci M., Pilotti E., Ronzi P., **ZIPETO D.**, Casoli C., Bertazzoni U.: "Delayed progression to AIDS in HTLV-II/HIV-1 coinfecting intravenous drug users". *AIDS Research and Human Retroviruses* 21 (5): 472 (2005). ISSN 0889-2229 [IF 2.375 - Q1/Q2]
67. **ZIPETO, D.**: "New vaccine strategies for chronic viral infections". *Drugs of the Future* 30 (2): 147-159 (2005) [IF 0.548 - Q3].
68. **ZIPETO, D.**, Bodaghi, B., Laurent, L., Virelizier, J.L., Michelson, M.: "Kinetics of transcription of human cytomegalovirus (HCMV) chemokine receptor US28 in different cell types". *Journal of General Virology* 80: 543-547 (1999). [37 CIT – IF 3.061 – Q1]
69. Bodaghi, B., Slobbe-van Drunen, M. E., Topilko, A., Perret E., Vossen, R. C., van Dam-Mieras, M. C., **ZIPETO, D.**, Virelizier, J.L., LeHoang, P., Bruggeman, C. A., Michelson, S.: "Entry of human cytomegalovirus into retinal pigment epithelial and endothelial cells by endocytosis". *Investigative Ophthalmology and Visual Science* 40: 2598-2607 (1999). [93 CIT – IF 4.887 - Q2]
70. Bodaghi, B., Goureau, O., **ZIPETO, D.**, Laurent, L., Virelizier, J.-L., Michelson, S.: "Role of IFNγ-induced indoleamine 2,3 dioxygenase and inducible NO-synthetase in the replication of human cytomegalovirus in retinal pigment epithelial cells. *Journal of Immunology* 162, 957-964 (1999). [181 CIT –

IF 7.166 – Q1]

71. Bodaghi, B., Jones, T. R., **ZIPETO, D.**, Vita, C., Sun, L., Laurent, L., Arenzana-Seisdedos, F., Virelizier, J.-L., Michelson, S.: "Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells". *Journal of Experimental Medicine* 188, 855-866 (1998) [274 CIT – IF 14.384 – Q1]
72. **ZIPETO, D.**, Hong, C., Gerna, G., Zavattoni, M., Katzenstein, D., Merigan, T. C., Rasmussen, L.: "Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients". *AIDS Research and Human Retroviruses* 14, 533-536 (1998). [49 CIT – IF 3.069 – Q1]
73. Rasmussen, L., **ZIPETO, D.**, Wolitz, R. A., Dowling, A., Efron, B., Merigan, T.C.: "Risk for Retinitis in Patients with Acquired Immunodeficiency Syndrome Can Be Assessed by Quantitation of Threshold Levels of Cytomegalovirus DNA Burden in Blood". *Journal of Infectious Diseases* 176, 1146-1155 (1997). [32 CIT – IF 5.099* – Q1]
74. Michelson, S., Dal Monte, P., **ZIPETO, D.**, Bodaghi, B., Laurent, L., Oberlin, E., Arenzana-Seisdedos, F., Virelizier, J. L., Landini, M.P.: "Modulation of RANTES production by human cytomegalovirus (CMV) infection of fibroblasts. *Journal of Virology* 71, 6495-6500 (1997). [83 CIT – 5.821* – Q1]
75. Rasmussen, L., Hong, C., **ZIPETO, D.**, Morris, S., Sherman, D., Wolitz, R., Dowling, A., Warford, A., Miner, R., Drew, L., Chou, S., Merigan, T.: "Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus infected patients and immunocompromised allograft recipients". *Journal of Infectious Diseases*, 175, 179-184 (1997). [90 CIT – IF 5.099* – Q1]
76. **ZIPETO, D.**, Morris, S., Hong, C., Dowling, A., Wolitz, R., Merigan, T. C., Rasmussen, L.: "Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes". *Journal of Clinical Microbiology* 33, 2607-2611 (1995) [74 CIT – IF 3.783 – Q1]
77. Rasmussen, L., Morris, S., **ZIPETO, D.**, Fessel, J., Wolitz, R., Dowling, A. and Merigan, T. C.: "Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus infected patients could predict cytomegalovirus retinitis". *Journal of Infectious Diseases*, 171, 177-182 (1995). [105 CIT – IF 5.099* – Q1]
78. **ZIPETO, D.**, Sarasini, A., Rossi, F., Baldanti, F., Revello, M. G., Milanesi, G. and Gerna, G.: "Identification of Human Cytomegalovirus strain with immediate-early (IE) antigen-specific monoclonal antibody is prevented by point mutation in the IE gene". *Journal of Clinical Microbiology* 32, 1402-1405 (1994) [4 CIT – CIT – IF 3.783* – Q1]
79. Gerna, G., Baldanti, F., Sarasini, A., Furione, M., Percivalle, E., Revello, M. G., **ZIPETO, D.**, Zella, D. and the Italian Foscarnet Study Group: "Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in blood leukocytes and aqueous humor of AIDS patients with HCMV retinitis". *Antimicrobial Agents and Chemotherapy* 38, 38-44 (1994). [81 CIT – IF 3.560 – Q1]
80. **ZIPETO, D.**, Baldanti, F., Percivalle, E., Gerna, G., and Milanesi, G.: "Identification of a human cytomegalovirus mutant in the pp150 matrix phosphoprotein gene with a growth-defective phenotype" - *Journal of General Virology* 74, 1645-1648 (1993). [13 CIT – IF 2.863- Q1]
81. **ZIPETO, D.**, Baldanti, F., Zella, D., Furione, M., Cavicchini, A., Milanesi, G., and Gerna, G.: "Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reaction" - *Journal of Virological Methods* 44, 45-56 (1993). [80 CIT – IF 1.623 - Q3]
82. Gerna, G., **ZIPETO, D.**, Percivalle, E., Parea, M., Revello, M. G., Maccario, R., Peri, G., Milanesi, G.: "Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients". - *Journal of Infectious Diseases* 166, 1236-1244 (1992). [160 CIT – IF 5.099* – Q1]
83. **ZIPETO, D.**, Revello, M. G., Silini, E., Parea, M., Percivalle, E., Zavattoni, M., Milanesi, G., Gerna, G.: "Development and Clinical Significance of a Diagnostic Assay Based on the Polymerase Chain Reaction for Detection of Human Cytomegalovirus DNA in Blood Samples from Immunocompromised Patients" - *Journal of Clinical Microbiology* 30, 527-530 (1992). [76 CIT – IF 3.783* – Q1]
84. Gerna, G., **ZIPETO, D.**, Parea, M., Percivalle, E., Zavattoni, M., Gaballo, A., Milanesi, G.: "Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viremia" - *Molecular and Cellular Probes* 5, 365-374 (1991) [29 CIT – IF 1.11* – Q3]
85. Gerna, G., **ZIPETO, D.**, Parea, M., Revello, M. G., Silini, E., Percivalle, E., Zavattoni, M., Grossi, P., Milanesi, G.: "Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia and DNAemia". - *Journal of Infectious Diseases* 164, 488-498 (1991). [289 CIT – IF 5.099* – Q1]
86. Gerna, G., Parea, M., Percivalle, E., **ZIPETO, D.**, Silini, E., Barbarini, G., Milanesi, G.: "Human cytomegalovirus viremia in HIV-1 seropositive patients at various clinical stages of infection". - *AIDS* 4: 1027-1031 (1990). [79 CIT – IF 5.050* – Q1]
87. **ZIPETO, D.**, Silini, E., Parea, M., Percivalle, E., Zavattoni, M., Di Matteo, A., Milanesi, G., Gerna, G.: "Identification of human cytomegalovirus isolates by the polymerase chain reaction" - *Microbiologica* 13, 297-304 (1990) [16 CIT – IF 4.064 – Q3]

Publicazioni disponibili come pre-print:

1. Grandi A., Tomasi M., Bertelli C., Vanzo T., Accordini S., Gagliardi A., Caproni E., Tamburini S., Fantappiè L., Di Lascio G., Bisoffi Z., Piubelli C., Valenti M.T., Dalle Carbonare L., **ZIPETO D.**, Iannaccone M., Cherepanov P., Bolognesi M., Pizzato M., Grandi G.: "Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine". *bioRxiv*, DOI: 10.1101/2021.07.12.452027
2. Ruggiero A., Piubelli C., Calciano L., Accordini S., Valenti M.T., Dalle Carbonare L., Siracusano G., Lopalco L., Temperton N., Tiberti N., Longoni S.S., Pizzato M., Accordini S., Fantoni T., AMSLV group, Beretta A., Bisoffi Z., **ZIPETO D.**: "SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals". *SSRN Electronic Journal*, id3956430, DOI: 10.2139/ssrn.3956430 (2021) [published on eBioMedicine, 2022]
3. Dalle Carbonare L., Valenti M.T., Bisoffi Z., Piubelli C., Pizzato M., Accordini S., Mariotto S., Ferrari S., Minoia A., Bertacco J., Li Vigni V., Dorelli G., Crisafulli E., Alberti D., Masin L., Tiberti N., Longoni S.S., Lopalco L., Beretta A., **ZIPETO D.**: "Antibody response to BTN162b2 vaccination in naïve versus SARS-CoV-2 infected subjects with and without waning immunity". *Research Square*, version 1, PPR32011, DOI: 10.21203/rs.3.rs-440410/v1 (2021) [published on Communications Medicine, 2021]

Capitoli di libri:

1. Fochi S., Bergamo E., Serena M., Mutascio S., Journo C., Mahieux R., Ciminale V., Bertazzoni U., **ZIPETO D.**, Romanelli M.G.: "TRAF3 is required for NF- κ B pathway activation mediated by HTLV tax proteins". In "HTLV-1: addressing unmet research need", Edited by L.M. Mansky and W. Zhang, 2021. ISSN 1664-8714 – ISBN 978-2-88966-790-1. Pag. 76-90.
2. Valenti M.T., Dalle Carbonare L., **ZIPETO D.**, Mottes M.: "Control of the autophagy pathway in osteoarthritis: key regulators, therapeutic targets, therapeutic strategies". In "Osteoarthritis From Molecular Pathways to Therapeutic Advances". Edited by Nicola Veronese 2021, ISBN 978-3-0365-3463-3. Pag. 249-

263.

3. **ZIPETO, D.**, Cavicchini, A., Baldanti, F., Furione, M., Milanesi, G., Gema, G.: "Quantificazione del DNA di citomegalovirus umano (HCMV) nei leucociti di pazienti immunocompromessi mediante polymerase chain reaction". In: "Oligonucleotidi Sintetici in Diagnostica Molecolare", R. Gambari, C. Nastruzzi, R. Piva Editors, Ferrara, October 1992: p. 1-6.
4. Gema, G., **ZIPETO, D.**, Parea, M., Revello, M. G., Silini, E., Percivalle, E., Zavattoni, M., Grossi, P., Minoli, L.: "Monitoring of human cytomegalovirus (HCMV) infections and DHPG treatment in heart transplant recipients (HTRs) by the polymerase chain reaction (PCR)" - In: "Progress in Cytomegalovirus Research", M. P. Landini Editor. 1991 Elsevier Science Publishers B. V.; pag. 19-22.
5. **ZIPETO, D.**, Silini, E., Parea, M., Percivalle, E., Gema, G., Milanesi, G.: "Impiego di oligonucleotidi sintetici per la diagnosi di viremia da citomegalovirus umano mediante polymerase chain reaction" - In: "Oligonucleotidi Sintetici in Biologia Molecolare e Biotecnologia", R. Gambari e C. Nastruzzi Editors, Ferrara, November 1990; pag. 83-86.

Atti di convegni, congressi, workshop:

1. Bianco S., Meneghel M., Voi M., Lorenzi P., Minoia A., Gandini A., Piritore F.C., Vareschi A., Romanelli M.G., **ZIPETO D.**, Dalle Carbonare L., Valenti M.T.: "FBXW11 as a Potential Modulator of Wnt/ β -Catenin Signaling and Autophagy in Osteosarcoma". XXIV National Conference A.I.B.G., Camogli (Italy) 22-24 October 2026.
2. Messina G., Bissoli M., Voi M., Orlandi E., Balestro M., Testi M., **ZIPETO D.**, Perrino C., Le Donne L., Ruggiero A.: "Phosphoproteomic profiling of laser-induced fibroblast activation: a molecular approach to regenerative pathways in planar fasciopathy". XVIII FISV Congress, Milan, Italy. 21-23 September 2026.
3. Campese A., Bissoli M., Orlandi E., Bombieri C., **ZIPETO D.**, Piubelli C., Temperton N.J., Castelli M., Ruggiero A.: "Abrogation of specific glycosylation sites on SARS-CoV-2 spike enhance virus infectivity and modulate antibody neutralizing activity". SIBBM 2026 – Frontiers in Molecular Biology. Siena, Italy. 16-18 June 2026.
4. De Martinis C., Bissoli M., Voi M., Orlandi E., Belay M. Ghiglione A., Robotti E., Ruggiero A. **ZIPETO D.**: "Functional interplay between ACOT8 and Nef enhances HIV-1 infectivity and remodels the viral envelope". SIBBM 2026 – Frontiers in Molecular Biology. Siena, Italy. 16-18 June 2026.
5. Tutela A., Zotti T., Madera J.R., Grasso G., Zerillo L., Martini M., Salerno E., Bergantino G.L., Sasso B., Albanese A., Lotrecchiano R., Orlandi E., Piubelli C., Grazioso G., Stilo R., **ZIPETO D.**, Vito P.: "Description of IgG and IgM microreactivity to immunogenic SPIKE-SARS-CoV-2 peptides in vaccinated patients". Congress of the Italian Society of Genetics (AGI), Bari, Italy, 17-19 September 2025. P50.
6. Ben Hklifa E., Campese A., Federico C., Tarcisio T., Da Costa K., Bissoli M., Orlandi E., Castelli M., **ZIPETO D.**, Temperton N.J., Ruggiero A.: "Functional implications of post-translational modifications (PTMs) on respiratory viruses and host interactions: preliminary analysis using different cell models". EvOx25, Emerging Viruses 2025, Oxford (UK), 3 September 2025.
7. Voi M., Sangalli A., Milano E.G., De Martinis C., Orlandi E., Tamburin S., Mantovani E., Federico A., Lanzafame M., Lattuada E., Arganaraz G.A., Da Silva B.C.M., Da Silva A.J.D., Casseb J., Arganaraz E.R., Ruggiero A., Valenti M.T., Grazioso G., **ZIPETO D.**: "A precise characterisation of peptide binding stability to HLA-C alleles and correlation with the progression of HIV-1 infection and HIV-1 related neurocognitive impairment". SIBBM 2025 – Frontiers in Molecular Biology. Naples, Italy. 17-19 June 2025. P.140 pag. 172.
8. Vareschi A., Gaglio S.C., Dervishi K., Zanella G., Minoia A., Jimenez-Lopez C. **ZIPETO D.**, Dalle Carbonare L., Gaboreanu D., Barbu I.C., Massimiliano P., Valenti M.T.: "Activity of methyl-ester sulphonate detergent combined with silver-derivatized magnetic nanoparticles". SIBBM 2025 – Frontiers in Molecular Biology. Naples, Italy. 17-19 June 2025. P.137 pag. 169.
9. De Martinis C., Dobre E.G., Voi M., Orlandi E., Bissoli M., Constantin C., Neagu M., Valenti M.T., **ZIPETO D.**: "Editing RUNX2 KO in B16 melanoma cells with CRISPR/Cas9 as a potential strategy to enhance in vivo tumor response to therapeutic approaches". SIBBM 2025 – Frontiers in Molecular Biology. Naples, Italy. 17-19 June 2025. P.39 pag. 71.
10. Dobre E.G., Voi M., Orlandi E., De Martinis C., Constantin C., **ZIPETO D.**, Valenti M.T., Neagu M.: Investigating the biological roles of the Runt domain of RUNX2 in cutaneous melanoma through targeted ablation". Bioinformatics Horizons '25, Bucharest, Romania, April 24, 2025.
11. Dobre E.G., Voi M., Orlandi E., De Martinis C., Constantin C., **ZIPETO D.**, Valenti M.T., Neagu M.: "Investigating RUNX2 KO in B16 melanoma cells as a potential strategy to enhance in vivo tumour response to therapeutic approaches". 8th International Conference, Cancer Immunotherapy & Immunomonitoring (CITIM), Bucharest, Romania, March 31-April 3, 2025. SEE J Immunol [Internet]. 2025 Mar. 25 [cited 2025 Mar. 31];8(CITIM):065. Available from: <https://seejim.eu/index.php/seejim/article/view/6121>. DOI: <https://doi.org/10.3889/seejim.2025.6121>
12. Dobre E.G., Voi M., Orlandi E., De Martinis C., Constantin C., **ZIPETO D.**, Valenti M.T., Neagu M.: "Establishing a workflow for assessing the roles of Runt domain of RUNX2 in B16 melanoma cells through targeted ablation". 8th International Conference, Cancer Immunotherapy & Immunomonitoring (CITIM), Bucharest, Romania, March 31-April 3, 2025.
13. Bissoli M., Voi M., Campese A., Stefani C., Palmeira J.F., Arganaraz E.R., Ruggiero A., **ZIPETO D.**: "The absence of human thioesterase ACOT8 negatively affects HIV-1 infectivity in vitro". SIBBM 2024 Frontiers in Molecular Biology, 17-19 June 2024. A.5, pag. 35.
14. Voi M., Dezhgir A., Siragusa A., Ruggiero A., Cecconi D., **ZIPETO D.**: "CRISPR/Cas9-mediated generation of HADHA KO PANC-1 cells to study the role of HADHA in pancreatic cancer stemness". SIBBM 2024 Frontiers in Molecular Biology, 17-19 June 2024. B.31, pag. 92.
15. Bissoli M., Stefani C., Voi M., Casula R., Corsi A., Romanelli M.G., Arganaraz E.R., da Fonseca Palmeira J., Ruggiero A., **ZIPETO D.**: "Human Thioesterase ACOT8 has an impact on in vitro HIV-1 infectivity". SIBBM 2023 Frontiers in Molecular Biology, Bari (Italy) 26-28 June 2023. P.4, pag. 49.
16. Vareschi A., Piritore F., Minoia A., Zouari S., Meneghel M., Ceretti L., Lorenzi P., **ZIPETO D.**, Romanelli M.G., Dalle Carbonare L., Valenti M.T.: "RUNX2 promotes metastatic ability of melanoma cells Trento (Italy) by increasing CXCR4 expression". SIBBM 2023 Frontiers in Molecular Biology, Bari (Italy) 26-28 June 2023. P.49, pag. 94.
17. Corsi A., Bombieri C., Trabetti E., Stefani C., Lorenzi P., Bruno M.G., Valentino A., Ruggiero A., Valenti M.T., **ZIPETO D.**, Romanelli M.G.: "Tau exon 6 alternative splicing is regulated by the RNA binding proteins PTBP1 and RBM20". SIBBM 2023 Frontiers in Molecular Biology, Bari (Italy) 26-28 June 2023. P.9 pag. 54.
18. Piubelli C., Ruggiero A., Calciano L., Mazzi C., Castilletti C., Tiberti N., Caldrea S., Verzè M., Longoni S.S., Accordini S., Bisoffi Z., **ZIPETO D.**: "SARS-CoV-2 vaccinees eliciting an unconventional IgM/IgG response show a less durable humoral immunity and an increased risk of infection". 7th National Congress of the Italian Society for Virology (SIV), Brescia, Italy, June 25-27, 2023. PO 147, pag. 204.
19. Stefani C., Sangalli A., Locatelli E., Federico T., Malerba G., Romanelli M.G., Arganaraz G.A., Da Silva B.C.M., Duarte Da Silva A.J., Casseb J., Arganaraz E.R., Ruggiero A., **ZIPETO D.**: "Influence of HLA-C genotype on HIV-1 progression". 7th National Congress of the Italian Society for Virology (SIV), Brescia, Italy, June 25-27, 2023. PO 112, pag. 168.
20. Ruggiero A., Stefani C., Sangalli A., Locatelli E., Federico T., Malerba G., Romanelli M.G., Arganaraz G.A., Da Silva Bosco C.M., Duarte Da Silva A.J.,

- Casseb J., Arganaraz E.R., **ZIPETO D.**: "HIV-1 rapid progressor patients present increased prevalence of unstable HLA-C variants". BHIVA, 2023 Spring Conference, 24-26 April 2023 Gateshead, UK. P020
21. Ruggiero A., Piubelli C., Calciano L., Mazzi C., Castilletti C., Tiberti N., Calderr S., Verzé M., Longoni S.S., Accordini S., Bisoffi Z., **ZIPETO D.**: "Lower breakthrough infection rate in individuals with postvaccination SARS-CoV2 IgM". CROI 2023, February 19-22 2023, Seattle, WA, USA. Abstract ID 1422574.
 22. Fantoni T., Mayora-Neto M., Dalle Carbonare L., Valenti M.T., Minoia A., Bertacco J., Dorelli G., Ruggiero A., Temperton N., **ZIPETO D.**: "Decay of neutralization activity in vaccinees receiving anti-SARS-CoV-2 3rd booster dose BNT162b2". Conference "Young Minds at Work: Blending Biology and Bioinformatics. December 2022, pag. 14.
 23. Locatelli E., Treccani M., Patuzzo C., Veschetti L., De Tomi E., Dagnogo D., Gallinaro M., Stefani C., **ZIPETO D.**, Tamburin S., Malerba G.: "Testing the performance o the imputation of MHC region in large datasets when using different reference panels". XXV Congresso Nazionale SIGU, Trieste (Italy), 7-9.9.2022
 24. Piubelli C., Ruggiero A., Calciano L., Mazzi C., Verzé M., Calderr S., Castilletti C., Fantoni T., Accordini S., **ZIPETO D.**, Bisoffi Z.: "Development of Sars-Cov-2 Igm after 1st vaccine dose predicts longer immunity". 16th Vaccine Congress, 19.10.2022: P1.31 (<https://ssm.com/abstract=4251996>)
 25. Ruggiero A., Piubelli C., Calciano L., Castilletti C., Tiberti N., Longoni S.S., Accordini S., Bisoffi Z., **ZIPETO D.**: "Individuals who develop SARS-CoV-2 specific IgM-S following BNT162b2 vaccination showed longer humoral immunity and lower risk of infection". World Vaccine Congress, Barcelona (Spain), October 11-14, 2022.
 26. Ruggiero A., Piubelli C., Calciano L., Siracusano G., Valenti M.T., Dalle Carbonare L.G., Fantoni T., Lopalco L., Accordini S., Beretta A., Bisoffi Z., **ZIPETO D.**: "Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity". ICAR, Bergamo (Italy) June 14-16 2022. Abstract ID 82 - N.pgm: OP 126, pag. 196
 27. Ruggiero A., Piubelli C., Calciano L., Siracusano G., Valenti M.T., Dalle Carbonare L.G., Fantoni T., Lopalco L., Accordini S., Beretta A., Bisoffi Z., **ZIPETO D.**: "Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity". 6th International Congress of the Italian Society for Virology SIV, Naples (Italy), July 3-5, 2022. Abstract PO113 pag. 216
 28. Ruggiero A., Piubelli C., Valenti M.T., Dalle Carbonare L., Siracusano G., Lopalco L., Temperton N., Pizzato M., Accordini S., Fantoni T., Beretta A., Bisoffi Z., **ZIPETO D.**: "Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity". CROI 2022, February 12-16, 2022.
 29. Stefani C., Sangalli A., Locatelli E., Ruggiero A., Fantoni T., Argañaraz E.R., Argañaraz G.A., Bosco da Silva C.M., da Silva Duarte A.J., Casseb J., Malerba G., Romanelli M.G., **ZIPETO D.**: "Influence of HLA-C genotype on AIDS progression". CROI 2022, February 12-16, 2022.
 30. De Simone T., Stefani C., Fochi S., Patuzzo C., Corsi A., **ZIPETO D.**, Romanelli M.G.: "Identification of novel target for miR-34° generating CRISPR/Cas9 miR-34a knock-out human cell lines". 33rd Annual Conference AICC, Turin (Italy), 22-24 November 2021.
 31. Locatelli E., Moron Dalla Tor L., Treccani M., Veschetti L., De Tomi E., Stefani C., Tamburin S., **ZIPETO D.**, Trabetti E., Patuzzo C., Malerba G.: "Dissection of HLA-C gene region to investigate its association with complex traits". Online Summer School 2021: Genetic epidemiology of kidney function and chronic kidney disease", July 12-16, 2021. Pag. 1-6.
 32. Stefani C., Sangalli A., Locatelli E., Argañaraz G.A., Bosco da Silva C.M., da Silva Duarte A.J., Casseb J., Romanelli M.G., **ZIPETO D.**: "HLA-C stability and AIDS progression". SIBBM 2021 conference "Frontiers in Molecular Biology", Online, June 7-10, 2021. #77.
 33. De Simone T., Stefani C., Fochi S., Patuzzo C., **ZIPETO D.**, Romanelli M.G.: "Establishment and characterization of CRISPR/Cas9 miR-34a knockout HeLa cell line". SIBBM 2021 conference "Frontiers in Molecular Biology", Online, June 7-10, 2021. #27.
 34. Locatelli E., Patuzzo C., Moron Dalla Tor L., Veschetti L., Mori A., Trabetti E., **ZIPETO D.**, Malerba G.: "Studiare la regione HLA negli esomi". XXII Congresso Nazionale SIGU, Rome (Italy), 13-16 November 2019.
 35. **ZIPETO D.**, Mutascio S., Stefani C., Serena M., Parolini F., Fochi S., Romanelli M.G., Gibellini D.: "HIV-1 and HLA-C relationship: a matter of stability". 3rd national congress of the Italian Society for Virology, 2019. OC46, Pag. 48
 36. Valenti M.T., Deiana M., Serena M., Cheri S., Parolini F., Marchetto G., Mina M.M., Mori A., Gandini A., Antoniazzi F., Malerba G., Mottes M., **ZIPETO D.**, Dalle Carbonare L.G.: "The Runt domain of RUNX2 induces the migration of melanoma cells to bone". ASBMR 2018, Montreal (CA), September 28-October 1, 2018. Pag. 213
 37. Fochi S., Mutascio S., Lorenzi P., Galasso M., **ZIPETO D.**, Romanelli M.G.: "NF-kB-activation mediated by HTLV-1 transactivator Tax protein is impaired in TRAF3 knock-out cells". FISV 2018, 18-21 September 2018, Rome (Italy).
 38. Galasso M., Fochi S., Lorenzi P., Cavallini C., Lovato O., **ZIPETO D.**, Romanelli M.G., Scupoli M.T.: "Regulation of catalase expression in chronic lymphocytic leukemia cells". SIBBM 2018 congress Frontiers in Molecular Biology – 20-22 June 2018, Rome (Italy).
 39. Mutascio S., Fochi S., Lorenzi P., Galasso M., **ZIPETO D.**, Romanelli M.G.: "TRAF3 involvement in the NF-kB pathway deregulation mediated by HTLV-1 Tax protein". SIBBM 2018 congress Frontiers in Molecular Biology – 20-22 June 2018, Rome (Italy).
 40. Galasso M., Fochi S., Lorenzi P., Cavallini C., Lovato O., Dando I., Donadelli M., **ZIPETO D.**, Romanelli M., Scupoli M.T.: Regulation of catalase expression in chronic lymphocytic leukemia cells". SIBBM 2018 congress Frontiers in Molecular Biology – 20-22 June 2018, Rome (Italy). Pag. 52
 41. Fochi S., Mutascio S., Parolini F., **ZIPETO D.**, Romanelli M.G.: "HTLV antisense proteins role in the NF-kB modulation". Virology 2017 Conference, 30-31 October 2017, Toronto (Canada), p. 6.
 42. Parolini F., Biswas P., Serena M., Sironi F., Mutascio S., Muraro V., Guizzardi E., Malnati M., Beretta A., Romanelli M.G., **ZIPETO D.**: "HLA-C expression levels and binding stability to β 2m are involved in HIV-1 infectivity". 9th IAS Conference on HIV Science. 23-26 July 2017, Paris (France), pp. 226-227.
 43. Parolini F., Mutascio S., Serena M., Fochi S., Romanelli M. G., **ZIPETO D.**: "CRISPR/Cas9 to study virus-host interactions" SIBBM congress 'From Single Cells to 3D-Cell Culture' - Milan (Italy). P.68. 14-16 June, 2017.
 44. Fochi S., Mutascio S., Parolini F., **ZIPETO D.**, Romanelli M.G.: "HTLV-1 basic leucine zipper factor and its homologous APH-2 impair NF-kB activation mediated by the viral oncoprotein tax". Life Science for a Better Future. AIBG 2017.
 45. Fochi S., Mutascio S., Parolini F., **ZIPETO D.**, Romanelli M.G.: "Host-virus interactions: HTLV antisense regulatory proteins play a role in the dysregulation of NF-kB pathway" - SIBBM congress 'From Single Cells to 3D-Cell Culture' - Milan (Italy). P. 28. 14 - 16 June, 2017.
 46. Cheri S., **ZIPETO D.**, Deiana M., Serena M., Parolini F., Gandini A., Mina, M., Mutascio S., Visser A., Mottes M., Dalle Carbonare L., Valenti M. T.: "CRISPR/Cas9 genome editing in melanoma cells: new insight of RUNT domain". 6th Sardinian International Summer School 'From Genome-wide association studies (GWAS) to function'. P. 4. Pula (Italy) - 12 - 16 June 2017.
 47. Valenti MT., **ZIPETO D.**, Deiana M., Serena M., Parolini F., Cheri S., Gandini A., Mina M., Mutascio S., Viser A., Dalle Carbonare L.: "CRISPR/Cas9 mediated knock-out of RUNX2 in melanoma cells". AICC Congress "The Future of Cancer Therapy: The Genome Editing Era", University Magna Grecia, Catanzaro, Italy, 8-9th June 2017. P 16.
 48. Fochi S., Mutascio S., Parolini F., **ZIPETO D.**, Romanelli M.G.: "A CRISPR/Cas9 based approach to study the implication of HTLV regulatory proteins in the NF-kB modulation". AICC Congress "The Future of Cancer Therapy: The Genome Editing Era", University Magna Grecia, Catanzaro, Italy, 8-9th June 2017.

Abstract Book AICC 2017, P47.

49. Parolini F., Mutascio S., Serena M., Fochi S., Romanelli M.G., **ZIPETO D.**: "CRISPR/Cas9 for the study of the interactions between viruses and host". AICC Congress "The Future of Cancer Therapy: The Genome Editing Era", University Magna Grecia, Catanzaro, Italy, 8-9th June 2017. P17.
50. Parolini F., Mutascio S., Serena M., Fochi S., Romanelli M. G., **ZIPETO D.**: "CRISPR/Cas9 as a tool for the study of the interactions between viruses and host". Dermatologic Spring In Iasi – HPV Symposium, 30.3.2017-1.4.2017, Iasi (Romania); Abstract Book, Pag. 72-73. ISBN:978-973-37-20-28-7.
51. Guizzardi E., Nicolis E., Gandis A.R., Gaio M., Arena S., Gandini G., Parolini F., Serena M., Romanelli M.G., **ZIPETO D.**: "Il ruolo di HLA-C nell'infezione da HIV-1". XXIII Congresso Nazionale AIBT, L'Aquila, 6-8 Ottobre 2016. Abstract Book, Pag. 147-148.
52. Serena M., Parolini F., Zoratti E., Scupoli M., Romanelli M.G., **ZIPETO D.**: "CRISPR/Cas9 as a tool for studying the interactions between viral and cellular proteins" pag. 16 (selected oral presentation). 12th SIBBM Seminar Frontiers in Molecular Biology. Naples (Italy), 16-18 June 2016.
53. Fochi S., Bergamo E., Serena M., **ZIPETO D.**, Romanelli M.G.: "Human T-cell leukemia virus HBZ and APH-2 antisense proteins interaction with host factors and their involvement in NF- κ B activation". Pag. 59, P. 39. 12th SIBBM Seminar Frontiers in Molecular Biology. Naples (Italy), 16-18 June 2016.
54. Fochi S., Bergamo E., Serena M., **ZIPETO D.**, Romanelli M.G.: "HTLV-1 and HTLV-2 Tax, HBZ and APH-2 interaction with host factors: their involvement in cellular pathways regulation. HERN 2016, pp. 1-48. Bucarest, 20-22 May 2016.
55. Valenzuela-Fernandez A, Garcia-Exposito L., Ziglio S., Barroso-Gonzales S., De Armas-Rillo L., Valera M. S. Marrero Hernandez S., **ZIPETO D.**, Machado J.D.: "Gelsoin activity controls efficient early HIV-1 infection". VII Congreso Nacional GeSIDA, Madrid (Spain), 1-4 December, 2015.
56. Serena M., Parolini F., Giorgietti A., Busato M., Gasparini F., Diani E., Romanelli M. G., **ZIPETO D.**: "In silico structural prediction and in vitro functional validation identify the ACOT8 regions involved in the interaction with HIV-1 Nef". The 27th International Workshop on Retroviral Pathogenesis, Mülheim an der Ruhr, Germany, August 24-27, 2015; pp. 77-79.
57. Bergamo E., Diani E., Fochi S., Lorenzi P., Serena M., **ZIPETO D.**, Romanelli M. G.: "The human T-cell leukemia virus-2 (HTLV-2) antisense protein APH-2 interacts with p65 and inhibits NF- κ B Tax-2 Activation". SIBBM 2015 Frontiers in Molecular Biology, Turin, Italy, July 1-3, 2015.
58. Serena M., Gasparini F., Astone D., Calligaris C., Muddei M., Giorgietti A., **ZIPETO D.**: "Human Thioesterase 8/HIV-1 Nef interaction: insights from in silico predictions and in vitro assays". 16th Annual International Meeting, Institute of Human Virology, Baltimore (USA), September 14-17, 2014.
59. Astone D., Racchioli P., Ziglio S., **ZIPETO D.**: "Development of chimeric humanized monoclonal antibodies against HIV-1". Europrise Network Annual Conference, Prague (Czech Republic), 14-17 November 2011. P02, pag. 29.
60. Ziglio S., Astone D., Danesin G., Racchioli P., Blanco A., **ZIPETO D.**: "HIV-1 Env glycoprotein and HLA-C associate and increase HIV-1 infectivity". Europrise Network Annual Conference, Prague (Czech Republic), 14-17 November 2011: pag. 26-27.
61. Ziglio S., Astone D., Danesin G., Racchioli P., Blanco A., **ZIPETO D.**: "Association analysis between HIV-1 Env and HLA-C using bimolecular fluorescence complementation". 13th Annual International Meeting, Institute of Human Virology, Baltimore (USA), October 30-November 2, 2011. Abs. n. C4, Pag. 78.
62. **ZIPETO D.**, Beretta A.: HIV-1 Env and HLA-C: Friends or Foes? 13th Annual International Meeting, Institute of Human Virology, Baltimore (USA), October 30-November 2, 2011. Abs. n. C3, Pag. 77.
63. Blanco A., Ziglio S., Racchioli P., Astone D., Turci M., **ZIPETO D.**: "HLA-C increased HIV-1 infectivity by interacting with the envelope glycoprotein gp120". Rational Design of HIV Vaccines and Microbicides. Europrise Network Annual Conference, Lisbon, Portugal, 15-18 November 2010. Pag. 21-22.
64. Turci M., Racchioli P., Ziglio S., Astone D., Blanco A., **ZIPETO D.**: "HLA-C associates with Env and increases HIV-1 infectivity". 12th Annual International Meeting of the Institute of Human Virology, Tropea (Italy), October 4-8, 2010 P. 157.
65. Astone D., Rossolillo P., Matucci A., Racchioli P., Cara A., **ZIPETO D.**: "Fusion complexes and CD4-independent Env for the induction of broad spectrum neutralizing antibodies against HIV-1". 12th Annual International Meeting of the Institute of Human Virology, Tropea (Italy), October 4-8, 2010. P. 157a.
66. Tamanini A., Astone D., Bertazzoni U., Bertolaso L., Bifari F., Celegato B., Chilosi M., Cozzi E., Dehecchi M. C., Gusella M., Krampera M., Lisi V., Ricciardi M., Turci M., **ZIPETO D.**: "Nuovi approcci per la cura della Fibrosi Cistica mediante terapia genica e cellulare". Convegno "Il Veneto per la Ricerca Socio Sanitaria – Implicazioni regionali, nazionali ed europee. Piazzola sul Brenta (Italy), September 16-17, 2010.
67. Turci M., Racchioli P., Astone D., **ZIPETO D.**: "HLA-C presence increases human immunodeficiency type 1 (HIV-1) infectivity by interacting with the envelope glycoprotein gp120/41". 4th European Congress of Virology, Cernobbio, Como (Italy), 7-11 April 2010. N. 248, p. 264.
68. Astone D., Rossolillo P., Matucci A., Racchioli P., Ruggiero A., **ZIPETO D.**: "Broad spectrum neutralizing antibodies against HIV-1 elicited by immunizing with fusion complexes and CD4-independent gp120/41s". Europrise Network Annual Conference, Budapest (Hungary), 15-18 November 2009; pag.10.
69. Astone D., Rossolillo P., Matucci A., Racchioli P., Ruggiero A., **ZIPETO D.**: "New immunogens for the induction of broad spectrum neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1)". 9th National Congress of the Italian Society of Virology, Orvieto, 7-9 September 2009. P47, pag. 52.
70. Turci M., Racchioli P., Astone D., Ruggiero A., Siccardi A., Beretta A., **ZIPETO D.**: "HLA-C presence increases human immunodeficiency virus type 1 (HIV-1) infectivity by interacting with the envelope glycoprotein gp120/41". 9th National Congress of the Italian Society of Virology, Orvieto, 7-9 September 2009. P18, pag. 29.
71. Rossolillo P., Matucci A., Racchioli P., Mainetti L., Dispinseri S., Scarlatti G., **ZIPETO D.**: "Broad spectrum neutralizing monoclonal antibodies against HIV-1 elicited by immunizing with fusion complexes". Rational Design of HIV Vaccines and Microbicides – Europrise Network Annual Conference, Malta, 10-13 November 2008. P28, pag. 31.
72. Matucci A., Rossolillo P., Turci M., Racchioli P., Siccardi A.G., Beretta A., **ZIPETO D.**: "Presence and Role of HLA-C in HIV-1 Infection". 11th Annual International Meeting, Institute of Human Virology, Baltimore (SA), September 11-13, 2008; P137.
73. Rossolillo P., Matucci A., Racchioli P., Mainetti L., Dispinseri S., Scarlatti G., **ZIPETO D.**: "Broad Spectrum Neutralizing Antibodies Against HIV-1 Elicited by Immunizing with Fusion Complexes". 11th Annual International Meeting, Institute of Human Virology, Baltimore (SA), September 11-13, 2008; P143.
74. Matucci A., Rossolillo P., **ZIPETO D.**: "HLA-C increases HIV-1 infectivity". 25 Years of HIV. May 19-21, 2008, Institut Pasteur, Paris (France). P1-27, pag. 90.
75. Rossolillo P., Matucci A., Scarlatti G., **ZIPETO D.**: "Fusion complexes as immunogens for the induction of broad spectrum neutralizing antibodies against HIV-1". Rational Design of HIV Vaccines and Microbicides, Europrise, Novartis Siena (Italy), November 22-23, 2007; S2-04, pag. 4.
76. Matucci A., Rossolillo P., Baroni M., Siccardi A., **ZIPETO D.**: "Fusion efficiency between the HIV-1 envelope and the target cell membrane is enhanced by the presence of HLA-C molecules". Early Steps of the Virus Life Cycle: Molecular and Cellular Insights. Institut Pasteur, Paris (France), October 4-5, 2007; P59, pag. 100.
77. Baroni M., De Santis C., Soprana E., Matucci A., Rossolillo P., **ZIPETO D.**, Scarlatti G., Siccardi A. G.: "Demonstration of the role of HLA-C in HIV-1 infection by siRNA silencing". Early Steps of the Virus Life Cycle: Molecular and Cellular Insights. Institut Pasteur, Paris (France), October 4-5, 2007; P4, pag. 45.
78. Matucci A., Rossolillo P., Sala S., Lopalco L., Siccardi A., Bertazzoni U., **ZIPETO D.**: "HLA-C increases fusion efficiency between the HIV-1 envelope and the cell membrane and is part of the fusion complex". 2006 International Meeting of the Institute of Human Virology, Baltimore (USA) November 17-21, 2006,

- Abs. 369.
79. Matucci A., Rossolillo P., Bertazzoni U., Siccardi A., **ZIPETO D.**: "HLA class I increases the efficiency of fusion between the HIV-1 envelope and the target cell membrane and is part of the fusion complex between the gp120/gp41 and the cellular receptors". 8th ECEAR 2006 Conference, Naples (Italy) May 26-28, 2006, Abs. O.08 pag. 14.
 80. Rossolillo P., Matucci A., Ripamonti C., Scarlatti G., Hazan U., Lopalco L., Bertazzoni U., **ZIPETO D.**: "Fusion complexes and CD4-independent gp120s for the induction of broad spectrum anti HIV-1 neutralizing antibodies". 8th ECEAR 2006 Conference, Naples (Italy) May 26-28, 2006, Abs. P.27 pag. 36.
 81. Matucci A., Rossolillo P., Ripamonti C., Scarlatti G., Lopalco L., Hazan U., Bertazzoni U., **ZIPETO D.**: "Use of gp120-CD4-coreceptor fusion complexes and CD4-independent gp120s for the induction of HIV-1 neutralizing antibodies". 5th National Congress of The Italian Society of Virology, Orvieto (Italy) September 19-21, 2005, Abs. 6.17, pag. 87.
 82. **ZIPETO D.**, Matucci A., Rossolillo P., Ripamonti C., Scarlatti G., Hazan U., Bertazzoni U.: "Fusion complexes and CD4-independent gp120s for the induction of HIV-1 neutralizing antibodies". 2005 International Meeting of the Institute of Human Virology, Baltimore (USA) August 29 – September 2, 2005, Abs. 121, pag. 56.
 83. **ZIPETO D.**, Matucci A., Rossolillo P., Turci M., Ripamonti C., Scarlatti G., Bertazzoni U.: "Induction of HIV neutralizing antibodies using fusion complexed and a CD4-independent env". V Programma Nazionale di Ricerca sull'AIDS, Progress Report Meeting, Roma, 2-6 May 2005, pag. 297.
 84. Turci M., **ZIPETO D.**, Pilotti E., Ronzi P., Casoli C., Bertazzoni U.: "La coinfezione HIV-1/HTLV-II è associata ad un rallentamento della progressione AIDS". V Programma Nazionale di Ricerca sull'AIDS, Progress Report Meeting, Roma, 2-6 Maggio 2005, pag. 44.
 85. **ZIPETO D.**, Ripamonti C., Matucci A., Rossolillo P., Scarlatti G., Padovani G., Tridente G., Bertazzoni U.: "Induction of HIV-1 neutralizing antibodies by fusion complexes." 2004 International Meeting of the Institute of Human Virology, Baltimore (USA) October 31-November 4, 2004; Abs. 99, pag. 57.
 86. Turci M., Pilotti E., **ZIPETO D.**, Casoli C., Bertazzoni U.: "HTLV-II influence on AIDS progression in intravenous drug users co-infected with HIV-1." 2004 International Meeting of the Institute of Human virology, Baltimore (USA) October 31-November 4, 2004; Abs. 261, pag. 96.
 87. **ZIPETO D.**, Ripamonti C., Matucci A., Rossolillo P., Scarlatti G., Padovani G., Bertazzoni U.: "Induction of human immunodeficiency virus (HIV) neutralizing antibodies with fusion complexes." Vaccines 3. Frontiers in vaccine development. Institut Pasteur, Paris, France, October 7-822, 2004, Abs. n. 38/16.
 88. **ZIPETO D.**, Ripamonti C., Matucci A., Rossolillo P., Scarlatti G., Padovani G., Bertazzoni U.: "Induction of human immunodeficiency virus (HIV) broad spectrum neutralizing antibodies with fusion complexes." 4th National Congress of The Italian Society of Virology, Orvieto (Italy) September 20-22, 2004.
 89. Rossolillo P., Ripamonti C., Matucci A., Scarlatti G., Hazan U., Bertazzoni U., **ZIPETO D.**: "Expression of HIV-1 NDK m7 and m9 env genes in eukaryotic cells for the induction of HIV-1 neutralizing antibodies". 4th National Congress of The Italian Society of Virology, Orvieto (Italy) September 20-22, 2004.
 90. Fraccaroli M., Avesani L., De Battisti V., **ZIPETO D.**, Turci M., Pezzotti M., Bertazzoni U.: "Production of a candidate HIV-1 vaccine in transgenic tobacco plants". 4th National Congress of The Italian Society of Virology, Orvieto (Italy) September 20-22, 2004.
 91. Costantini S., **ZIPETO D.**, Turci M., Mina M. M., Menestrina F., Bertazzoni U.: "Detection and typing of Human Cytomegalovirus DNA in colorectal cancer". 4th National Congress of The Italian Society of Virology, Orvieto (Italy) September 20-22, 2004.
 92. Avesani L., Fraccaroli M., De Battisti V., **ZIPETO D.**, Turci M., Bertazzoni U., Pezzotti M.: "Expression of a candidate vaccine for AIDS prevention in transgenic tobacco plants". XLVIII Annual Congress, Società Italiana di Genetica Agraria, Lecce, Italy, September 15-18, 2004.
 93. Rossolillo P., Ripamonti C., Matucci A., Scarlatti G., Turci M., Hazan U., Bertazzoni U., **ZIPETO D.**: "Expression of HIV-1 NDK m9 env gene in eukaryotic cells for the induction of HIV-1 neutralizing antibodies". 3rd European Conference & Practical course on "Advanced Methods for industrial production, purification and characterization of gene vectors". 14-16 June 2004, Université d'Evry-Val d'Essonne, Genopole@Evry, France, pag. 45.
 94. Turci M., Romanelli M.G., **ZIPETO D.**, Toffalini F., Bertazzoni U.: "Expression and purification of recombinant HTLV-II Tax protein in E. Coli and in mammalian cells". HERN 2004, Halkidiki, Greece, June 4-6, 2004, pag. 25.
 95. Turci M., Pilotti E., **ZIPETO D.**, Casoli C., Bertazzoni U.: "HTLV-II influence on AIDS progression and changes in response to antiretroviral therapy in Italian IDUs coinfecting with HIV-1". HERN 2004, Halkidiki, Greece, June 4-6, 2004, pag. 30.
 96. **ZIPETO D.**, Matucci A., Ripamonti C., Scarlatti G., Turci M., Sartoris S., Andrighetto G., Bertazzoni U.: "Fusion complexes as broad spectrum anti-HIV vaccine". 2003 International Meeting of the Institute of Human Virology, Baltimore Waterfront Marriot, Baltimore, USA, Sept. 29.-Oct. 3, 2003, Abs. 87, pag.45-46.
 97. Turci M., Casoli C., Pilotti W., Ciancinaini P., **ZIPETO D.**, Bertazzoni U.: "Influence of HTLV-II infection on AIDS progression in injecting drug users co-infected by HIV-1". 2003 International Meeting of the Institute of Human Virology, Baltimore Waterfront Marriot, Baltimore, USA, Sept. 29.-Oct. 3, 2003, Abs. 257, pag.77.
 98. **ZIPETO D.**, Matucci A., Ripamonti C., Scarlatti G., Turci M., Sartoris S., Andrighetto G., Bertazzoni U.: "Study of the optimal conditions for obtaining fusion complexes to be used as broad spectrum anti HIV-1 vaccine". 3rd National Congress of the Italian Society of Virology (SIV), Cortona (AR), September 22-24, 2003.
 99. Turci M., **ZIPETO D.**, Matucci A., Casoli C., Bertazzoni U.: "Expression and purification of recombinant HTLV-2 Tax protein in mammalian cells". 3rd National Congress of the Italian Society of Virology (SIV), Cortona (AR), September 22-24, 2003.
 100. **ZIPETO D.**, Cosma A., LeGrand R., Erfle V., Siccardi A.G., Beretta A. Cell-based vaccination: rationale for the use of cells co-expressing HIV env gp120 and HLA class I Cw4 molecules for the induction of neutralizing antibodies. The 2nd IAS Conference on Pathogenesis and Treatment, Paris, France, 13-16 July 2003, pag. 151. Antiviral Therapy 8 (Suppl. 1) #S318 (2003).
 101. **ZIPETO D.**, Stella A., Siccardi A. G.: "Presence and role of HLA Class I in the HIV-1 induced fusion complex". ECEAR 2002, 7th European Conference on Experimental AIDS Research, Genova (Italy), June 8-11, 2002: AB 27, pag. 97.
 102. **ZIPETO D.**, Stella A., Lusso P., Sironi F., Bertazzoni U., Stegmann T.: "A new approach to the development of a broadly neutralizing anti-HIV vaccine". ECEAR 2002, 7th European Conference on Experimental AIDS Research, Genova (Italy), June 8-11, 2002: AB 45, pag. 107.
 103. Michelson S., Bodaghi B., Laurent L., **ZIPETO D.**, Virelizier J.-L.: "Cytomegalovirus et cytokines". 5ème Congrès Société Française de Microbiologie. Lille (France), April 27-29, 1998; pag. 93.
 104. Rasmussen L., **ZIPETO D.**, Wolitz R., Dowling A., Merigan T.: "Quantification of Human Cytomegalovirus DNA during Viremia identifies Risk for Retinitis in AIDS Patients". Evaluation and Management of AIDS-related CMV, Palo Alto, CA (USA), December 2, 1996; pag. 22.
 105. Rasmussen L., Hong C., Sherman D., **ZIPETO D.**, Chou S., Merigan T.: "Distribution of CMV Glycoprotein UL55 (gB) and UL75 (gH) Sequence Variant Groups in Patients Infected with HIV". 5th International Cytomegalovirus Conference, Stockholm (Sweden), May 21-24, 1995; P028, pag. 74.
 106. **ZIPETO D.**, Morris S., Hong C., Dowling A., Wolitz R., Merigan T. C., Rasmussen L.: "CMV DNA in plasma reflects CMV DNA in white blood cells (WBC) but is not related to symptomatic disease". 5th International Cytomegalovirus Conference, Stockholm (Sweden), May 21-24, 1995; P107, pag. 113.
 107. Baldanti F., Zella D., Furione M., **ZIPETO D.**, Gerna G.: "A simple method for human cytomegalovirus (HCMV) DNA quantitation in clinical samples". - IXth International Congress of Virology, Glasgow, 8-13 August 1993; pag. 242.

108. Gallina, A., Schiavone, N., **ZIPETO, D.**, Milanesi, G.: "Targeting of pMA fusion proteins to pericentrosomal cell sites". - IXth International Conference on AIDS, Berlin, June 6-11, 1993; Abstract Book Volume I, pag. 156.
109. **ZIPETO, D.**, Sarasini, A., Baldanti, F., Furione, M., Milanesi, G., Gerna, G.: "Human Cytomegalovirus (HCMV) viremia: false negative results in an AIDS patient due to a point mutation in the IE1 gene". - IXth International Conference on AIDS, Berlin, June 6-11, 1993; Abstract Book Volume I, pag. 358.
110. **ZIPETO, D.**, Baldanti, F., Percivalle, E., Gerna, G., Milanesi, G.: "Characterization of a human cytomegalovirus (HCMV) mutant in the pp150 gene" - 4th international CMV Conference. Paris, April 18-21, 1993; pag. 220.
111. Baldanti, F., **ZIPETO, D.**, Furione, M., Gerna, G.: "Rapid quantitation of human cytomegalovirus DNA by PCR in blood of immunocompromised patients". - European Group for Rapid Viral Diagnosis, Group Meeting, Wien, 2-5 September 1992.
112. Gerna, G., Percivalle, E., **ZIPETO, D.**, Baldanti, F., Revello, M. G.: "Correlations between HCMV viremia, antigenemia, DNAemia and clinical symptoms". - Meeting "Cytomegalovirus: molecular tools for diagnosis and control of HCMV infections", Paris, May 15, 1992.
113. **ZIPETO, D.**, Parea, M., Baldanti, F., Percivalle, E., Revello, M. G., Milanesi, G., Gerna, G.: "Studio dell'espressione in vitro e in vivo degli mRNA immediati e tardivi di citomegalovirus umano" - Convegno congiunto SIBBM/AGI, Porto Conte-Alghero, 2-5 Ottobre 1991; Atti SIBBM, pag. 161-162.
114. Baldanti, F., **ZIPETO, D.**, Silini, E., Gerna, G., Milanesi, G.: "Restriction fragment length analysis and single strand conformation analysis in the study of the molecular epidemiology of human cytomegalovirus" - Convegno congiunto SIBBM/AGI, Porto Conte-Alghero, 2-5 Ottobre 1991; Atti AGI, pag. 289-290.
115. **ZIPETO, D.**, Parea, M., Maccario, R., Peri, G., Baldanti, F., Gerna, G., Milanesi, G.: "In vivo identification of leukocyte subpopulations infected by human cytomegalovirus (HCMV) by mean of fluorescence activated cell sorting (FACS) and polymerase chain reaction (PCR)" - Convegno congiunto SIBBM/AGI, Porto Conte-Alghero, 2-5 Ottobre 1991; Atti AGI, pag. 187-188.
116. Silini, E., **ZIPETO, D.**, Baldanti, F., Di Matteo, A., Milanesi, G., Gerna, G.: "Detection of polymorphisms of human cytomegalovirus (HCMV) isolates using polymerase chain reaction (PCR) and single strand conformation polymorphisms (SSCP)" - European Group for Rapid Viral Diagnosis/European Society against Viral Diseases, Third Joint Meeting - Strasbourg, France, 25-29 August 1991: PS1-9.
117. Parea, M., **ZIPETO, D.**, Gaballo, A., Baldanti, F., Milanesi, G., Gerna, G.: "Comparison of liquid hybridization (LH) and DNA enzyme immunoassay (DEIA) as a specificity control for human cytomegalovirus (HCMV) DNA amplification product by the polymerase chain reaction (PCR)" - European Group for Rapid Viral Diagnosis/European Society against Viral Diseases, Third Joint Meeting - Strasbourg, France, 25-29 August 1991: PS1-75.
118. Gerna, G., **ZIPETO, D.**, Parea, M., Percivalle, E., Milanesi, G.: "Human Cytomegalovirus (HCMV) systemic infections in AIDS patients by PCR" - Seventh International Conference on AIDS - Florence, Italy, 16-21 June 1991: Abstract Book, Volume 2, pag. 270.
119. Gerna, G., **ZIPETO, D.**, Parea, M., Revello, M. G., Silini, E., Percivalle, E., Zavattoni, M., Grossi, P., Minoli, L.: "Monitoring of HCMV infections and DHPG treatment in heart transplant recipients (HTRs) by the polymerase chain reaction" - III° International Cytomegalovirus Workshop - Bologna, Italy, 11-14 June 1991: pag. 4.
120. **ZIPETO, D.**, Silini, E., Parea, M., Maccario, R., Peri, G., Percivalle, E., Milanesi, G., Revello, M. G., Gerna, G.: "In vivo interactions between HCMV and peripheral blood leukocytes" - III° International Cytomegalovirus Workshop - Bologna, Italy, 11-14 June 1991: pag. 107.
121. Gerna, G., **ZIPETO, D.**, Parea, M., Percivalle, E., Milanesi, G.: "Follow-up della viremia da citomegalovirus umano nei pazienti con AIDS" - III° Progetto di Ricerche sull'AIDS 1990, Progress Report - Orbetello (GR), 18-23 Maggio 1991: pag. 91.
122. Gerna, G., Revello, M. G., **ZIPETO, D.**, Parea, M., Percivalle, E.: "Diagnosis of Disseminated Human Cytomegalovirus (HCMV) Infection in Patients with AIDS" - General Meeting of the America Society for Microbiology, Dallas, Texas, 5-9 May 1991: pag. 353.
123. Gerna, G., Revello, M. G., Parea, M., **ZIPETO, D.**, Silini, E., Percivalle, E., Zavattoni, M.: "Viremia da citomegalovirus umano (HCMV): significato clinico e trattamento" - A.I.D.S. e sindromi correlate, IV Convegno Nazionale ANLAIDS, Sanremo, 30 November-2 December 1990: pag. 26.
124. Gerna, G., Revello, M. G., Percivalle, E., **ZIPETO, D.**, Silini, E., Parea, M., Zavattoni, M.: "Monitoraggio della viremia da citomegalovirus umano (HCMV) nel paziente immunocompromesso mediante test immunologici e PCR" - XXIII Congresso Nazionale Società Italiana di Microbiologia, Palermo, 26-30 November 1990: pag. 259.
125. **ZIPETO, D.**, Silini, E., Parea, M., Percivalle, E., Gerna, G., Milanesi, G.: "Polymerase chain reaction (PCR) in the study of cytomegalovirus viremia" - 36° Congresso Nazionale della Associazione Genetica Italiana, Perugia, 22-24 Ottobre 1990: pag. 277-288.
126. **ZIPETO, D.**, Silini, E., Parea, M., Peri, G., Maccario, R., Miranda, P., G. Gerna, G. Milanesi: "Analisi molecolare delle interazioni fra citomegalovirus umano e leucociti" - XXVII Convegno Scientifico SIBBM, Cortona (AR), 15-17 October 1990: pag. 127-128.
127. Gerna, G., Revello, M. G., **ZIPETO, D.**, Silini, E., Parea, M., Milanesi, G.: "Polymerase chain reaction (PCR) and monoclonal antibody (MAb) for rapid detection of human cytomegalovirus (HCMV) in peripheral blood leukocytes (PBL)". - VIIIth international congress of Virology, Berlin, August 26-31, 1990: pag. 307.
128. Gerna, G., **ZIPETO, D.**, Silini, E., Parea, M., Grossi, P., Milanesi, G.: "Early virus isolation, immediate-early antigen detection and DNA amplification by PCR in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viremia". - Sixth international conference on AIDS - San Francisco California USA, 20-24 June 1990: Volume 2 abstracts, pag. 380.
129. Gerna, G., Revello, M. G., Parea, M., Percivalle, E., **ZIPETO, D.**, Silini, E., Milanesi, G.: "Monitoraggio virologico delle infezioni da citomegalovirus umano (HCMV) nel paziente con AIDS". - Rapporti Istisan, secondo progetto di ricerche sull'AIDS, Orbetello (GR), 28 Maggio - 1° Giugno 1990: pag. 100.
130. **ZIPETO, D.**, Grasso, M., Silini, E., Di Matteo, A., Gerna, G., Milanesi, G.: "Rivelazione di infezione da citomegalovirus nei Polimorfonucleati ematici in corso di infezione naturale" - Joint conference SIBBM-AGI, Verona, 16-19 October 1989: pag. 160-161.